NO329692B1 - Forbindelser som er A2B-adenosinreseptorantagonister, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende forbindelsene og anvendelse av forbindelsene - Google Patents
Forbindelser som er A2B-adenosinreseptorantagonister, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende forbindelsene og anvendelse av forbindelsene Download PDFInfo
- Publication number
- NO329692B1 NO329692B1 NO20042378A NO20042378A NO329692B1 NO 329692 B1 NO329692 B1 NO 329692B1 NO 20042378 A NO20042378 A NO 20042378A NO 20042378 A NO20042378 A NO 20042378A NO 329692 B1 NO329692 B1 NO 329692B1
- Authority
- NO
- Norway
- Prior art keywords
- dione
- formula
- trihydropurine
- compound
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 435
- 238000000034 method Methods 0.000 claims abstract description 74
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 208000006673 asthma Diseases 0.000 claims abstract description 13
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims abstract description 10
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims abstract description 10
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 6
- 230000033115 angiogenesis Effects 0.000 claims abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 88
- 229910052739 hydrogen Inorganic materials 0.000 claims description 75
- 239000001257 hydrogen Substances 0.000 claims description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 72
- -1 3-trifluoromethylphenyl Chemical group 0.000 claims description 64
- 125000000217 alkyl group Chemical group 0.000 claims description 60
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 51
- 150000002431 hydrogen Chemical class 0.000 claims description 42
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 38
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 29
- 101150078577 Adora2b gene Proteins 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000002947 alkylene group Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 13
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 12
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 7
- 239000012458 free base Substances 0.000 claims description 7
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 150000004866 oxadiazoles Chemical class 0.000 claims description 5
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 5
- FJOWCRNUYDSBQY-UHFFFAOYSA-N 1,3-dipropyl-8-(1h-pyrazol-4-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C=1C=NNC=1 FJOWCRNUYDSBQY-UHFFFAOYSA-N 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- VKTXMHRAIBKAOF-UHFFFAOYSA-N 1,3-dipropyl-8-[1-[2-[3-(trifluoromethyl)phenyl]ethyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CCC1=CC=CC(C(F)(F)F)=C1 VKTXMHRAIBKAOF-UHFFFAOYSA-N 0.000 claims description 3
- QSEYHOMIGYEFFY-UHFFFAOYSA-N 1-butyl-8-[1-[[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]pyrazol-4-yl]-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)NC=2N=C1C(=C1)C=NN1CC(N=1)=NOC=1C1=CC=C(Cl)C=C1 QSEYHOMIGYEFFY-UHFFFAOYSA-N 0.000 claims description 3
- UDNGNWOKQLQPJV-UHFFFAOYSA-N 2-[4-[6-oxo-1-(2-oxopropyl)-3-propyl-2,7-dihydropurin-8-yl]-1H-pyrazol-5-yl]-2-phenylacetic acid Chemical compound O=C(CN1CN(C=2N=C(NC=2C1=O)C=1C(=NNC=1)C(C(=O)O)C1=CC=CC=C1)CCC)C UDNGNWOKQLQPJV-UHFFFAOYSA-N 0.000 claims description 3
- KOYXXLLNCXWUNF-UHFFFAOYSA-N 3-ethyl-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 KOYXXLLNCXWUNF-UHFFFAOYSA-N 0.000 claims description 3
- VKONPLGZIZPWGJ-UHFFFAOYSA-N 4-[[4-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)pyrazol-1-yl]methyl]benzoic acid Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=C(C(O)=O)C=C1 VKONPLGZIZPWGJ-UHFFFAOYSA-N 0.000 claims description 3
- HWHLLTUJISZFDN-UHFFFAOYSA-N 8-[1-[[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]pyrazol-4-yl]-1-propyl-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)NC=2N=C1C(=C1)C=NN1CC(N=1)=NOC=1C1=CC=C(Cl)C=C1 HWHLLTUJISZFDN-UHFFFAOYSA-N 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- IVDPFMFNQXHGNX-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1CC1=CC=CC(F)=C1 IVDPFMFNQXHGNX-UHFFFAOYSA-N 0.000 claims 1
- JBGRNTKBOQPADE-UHFFFAOYSA-N 1-butyl-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 JBGRNTKBOQPADE-UHFFFAOYSA-N 0.000 claims 1
- KAYVCWBEIZTVCN-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-1-propyl-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 KAYVCWBEIZTVCN-UHFFFAOYSA-N 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000005490 tosylate group Chemical class 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 4
- 208000025966 Neurological disease Diseases 0.000 abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 139
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- 239000000203 mixture Substances 0.000 description 66
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 61
- 230000002829 reductive effect Effects 0.000 description 55
- 125000001072 heteroaryl group Chemical group 0.000 description 53
- 239000002904 solvent Substances 0.000 description 51
- 125000003118 aryl group Chemical group 0.000 description 48
- 125000001424 substituent group Chemical group 0.000 description 45
- 239000000243 solution Substances 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 239000000047 product Substances 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 26
- 125000003545 alkoxy group Chemical group 0.000 description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 25
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 24
- 125000004181 carboxyalkyl group Chemical group 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 229920002554 vinyl polymer Polymers 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 21
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 125000003342 alkenyl group Chemical group 0.000 description 19
- 125000000623 heterocyclic group Chemical group 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 17
- 125000000753 cycloalkyl group Chemical group 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 125000000304 alkynyl group Chemical group 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 125000000392 cycloalkenyl group Chemical group 0.000 description 15
- 239000002585 base Substances 0.000 description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 14
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 13
- 229960005305 adenosine Drugs 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 12
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 125000004414 alkyl thio group Chemical group 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 10
- 239000012442 inert solvent Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 229930194542 Keto Natural products 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 125000004442 acylamino group Chemical group 0.000 description 9
- 125000004423 acyloxy group Chemical group 0.000 description 9
- 125000005110 aryl thio group Chemical group 0.000 description 9
- 125000004104 aryloxy group Chemical group 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 125000005553 heteroaryloxy group Chemical group 0.000 description 9
- 125000000468 ketone group Chemical group 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 125000000547 substituted alkyl group Chemical group 0.000 description 9
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 9
- 150000003573 thiols Chemical class 0.000 description 9
- 230000007306 turnover Effects 0.000 description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 8
- 125000000033 alkoxyamino group Chemical group 0.000 description 8
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 8
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 125000005368 heteroarylthio group Chemical group 0.000 description 8
- 125000004470 heterocyclooxy group Chemical group 0.000 description 8
- 125000004468 heterocyclylthio group Chemical group 0.000 description 8
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 8
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 239000005711 Benzoic acid Substances 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000003630 histaminocyte Anatomy 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- GZLZRPNUDBIQBM-UHFFFAOYSA-N 6-amino-1-methylpyrimidine-2,4-dione Chemical compound CN1C(N)=CC(=O)NC1=O GZLZRPNUDBIQBM-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 150000004820 halides Chemical class 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002798 polar solvent Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 5
- KGDOHXYALMXHLF-UHFFFAOYSA-N 1-benzylpyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1CC1=CC=CC=C1 KGDOHXYALMXHLF-UHFFFAOYSA-N 0.000 description 5
- CADWRZPSQGRYRW-UHFFFAOYSA-N 5,6-diamino-1-benzylpyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1CC1=CC=CC=C1 CADWRZPSQGRYRW-UHFFFAOYSA-N 0.000 description 5
- USWCRMBFRFQYQI-UHFFFAOYSA-N 5,6-diamino-3-butyl-1h-pyrimidine-2,4-dione Chemical compound CCCCN1C(=O)NC(N)=C(N)C1=O USWCRMBFRFQYQI-UHFFFAOYSA-N 0.000 description 5
- WDVYWEYJVBNHLX-UHFFFAOYSA-N 6-amino-1-benzyl-5-nitrosopyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1CC1=CC=CC=C1 WDVYWEYJVBNHLX-UHFFFAOYSA-N 0.000 description 5
- QMKJOZVQZBJSEC-UHFFFAOYSA-N 6-amino-1-benzylpyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1CC1=CC=CC=C1 QMKJOZVQZBJSEC-UHFFFAOYSA-N 0.000 description 5
- XBMQWAVBSYNIQO-UHFFFAOYSA-N 6-amino-3-butyl-1h-pyrimidine-2,4-dione Chemical compound CCCCN1C(=O)C=C(N)NC1=O XBMQWAVBSYNIQO-UHFFFAOYSA-N 0.000 description 5
- AFXRGDZUPUNBCX-UHFFFAOYSA-N 6-amino-3-butyl-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound CCCCN1C(=O)NC(N)=C(N=O)C1=O AFXRGDZUPUNBCX-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 5
- 235000010288 sodium nitrite Nutrition 0.000 description 5
- 125000003107 substituted aryl group Chemical group 0.000 description 5
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 5
- QEWJYMQUTCMVJI-UHFFFAOYSA-N tert-butyl 8-(4-hydroxyphenyl)-2,6-dioxo-1,3-dipropylpurine-7-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(O)C=C1 QEWJYMQUTCMVJI-UHFFFAOYSA-N 0.000 description 5
- LSYCZBSPYWGGHC-UHFFFAOYSA-N 3-(chloromethyl)-5-(4-methoxyphenyl)-1,2,4-oxadiazole Chemical compound C1=CC(OC)=CC=C1C1=NC(CCl)=NO1 LSYCZBSPYWGGHC-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- JNJWKLSCJORTLT-UHFFFAOYSA-N 8-[4-[[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC=C1OC JNJWKLSCJORTLT-UHFFFAOYSA-N 0.000 description 4
- 101150046889 ADORA3 gene Proteins 0.000 description 4
- 108050000203 Adenosine receptors Proteins 0.000 description 4
- 102000009346 Adenosine receptors Human genes 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- RJNJWHFSKNJCTB-UHFFFAOYSA-N benzylurea Chemical compound NC(=O)NCC1=CC=CC=C1 RJNJWHFSKNJCTB-UHFFFAOYSA-N 0.000 description 4
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 4
- 230000001593 cAMP accumulation Effects 0.000 description 4
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 150000005071 1,2,4-oxadiazoles Chemical class 0.000 description 3
- IDMQLXNSDSLNNR-UHFFFAOYSA-N 1,3-dipropyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 IDMQLXNSDSLNNR-UHFFFAOYSA-N 0.000 description 3
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- MZIXESWKJVPVOE-UHFFFAOYSA-N 2-[4-[2,6-dioxo-7-(phenylmethoxymethyl)-1,3-dipropylpurin-8-yl]phenoxy]acetonitrile Chemical compound C=1C=CC=CC=1COCN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(OCC#N)C=C1 MZIXESWKJVPVOE-UHFFFAOYSA-N 0.000 description 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
- SVMBOONGPUFHRA-UHFFFAOYSA-N 5,6-diamino-1,3-dipropylpyrimidine-2,4-dione Chemical compound CCCN1C(N)=C(N)C(=O)N(CCC)C1=O SVMBOONGPUFHRA-UHFFFAOYSA-N 0.000 description 3
- LNDZXOWGUAIUBG-UHFFFAOYSA-N 6-aminouracil Chemical compound NC1=CC(=O)NC(=O)N1 LNDZXOWGUAIUBG-UHFFFAOYSA-N 0.000 description 3
- VUCFOFXDFGNTRU-UHFFFAOYSA-N 7-benzyl-1,3-dipropylpurine-2,6-dione Chemical compound C1=2C(=O)N(CCC)C(=O)N(CCC)C=2N=CN1CC1=CC=CC=C1 VUCFOFXDFGNTRU-UHFFFAOYSA-N 0.000 description 3
- RFZNLAAXZWFSJF-UHFFFAOYSA-N 7-benzyl-8-chloro-1,3-dipropylpurine-2,6-dione Chemical compound C1=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C(Cl)N1CC1=CC=CC=C1 RFZNLAAXZWFSJF-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- BXQRCUSBUDNKKE-UHFFFAOYSA-N 8-[1-[(2-methoxyphenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1OC BXQRCUSBUDNKKE-UHFFFAOYSA-N 0.000 description 3
- NJXVKVMVLZPERB-UHFFFAOYSA-N 8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 NJXVKVMVLZPERB-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000055025 Adenosine deaminases Human genes 0.000 description 3
- 101150051188 Adora2a gene Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- 229960000278 theophylline Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- FEJTVTKGBCCGCQ-UHFFFAOYSA-N 1,3-dipropyl-8-[4-[[5-[2-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC=C1OC(F)(F)F FEJTVTKGBCCGCQ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FXQDKELSCFTQDH-UHFFFAOYSA-N 1-(3-phenylpropyl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1CCCC1=CC=CC=C1 FXQDKELSCFTQDH-UHFFFAOYSA-N 0.000 description 2
- NUMOUMWZKQANSP-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-methyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound O=C1N(C)C=2N=C(C3=CN(CC=4C=C(C=CC=4)C(F)(F)F)N=C3)NC=2C(=O)N1CC1CC1 NUMOUMWZKQANSP-UHFFFAOYSA-N 0.000 description 2
- YFYXWQMWEPIKKV-UHFFFAOYSA-N 1-butan-2-yl-3-ethyl-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C(C)CC)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 YFYXWQMWEPIKKV-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- VODKOOOHHCAWFR-UHFFFAOYSA-N 2-iodoacetonitrile Chemical compound ICC#N VODKOOOHHCAWFR-UHFFFAOYSA-N 0.000 description 2
- ZOWLLEBVXDSRDI-UHFFFAOYSA-N 3-(chloromethyl)-5-(2-methoxyphenyl)-1,2,4-oxadiazole Chemical compound COC1=CC=CC=C1C1=NC(CCl)=NO1 ZOWLLEBVXDSRDI-UHFFFAOYSA-N 0.000 description 2
- CGSXQKBHWUONAL-UHFFFAOYSA-N 3-benzyl-8-(1-benzylpyrazol-4-yl)-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(C3=CN(CC=4C=CC=CC=4)N=C3)=NC=2N1CC1=CC=CC=C1 CGSXQKBHWUONAL-UHFFFAOYSA-N 0.000 description 2
- XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 2
- FSZJGDMXEQVTPM-UHFFFAOYSA-N 3-butan-2-yl-1-methyl-8-(1h-pyrazol-4-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C)C(=O)N(C(C)CC)C=2N=C1C=1C=NNC=1 FSZJGDMXEQVTPM-UHFFFAOYSA-N 0.000 description 2
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 description 2
- BWVLVKYENDCAHC-UHFFFAOYSA-N 3-methyl-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 BWVLVKYENDCAHC-UHFFFAOYSA-N 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- PSIJQVXIJHUQPJ-UHFFFAOYSA-N 5,6-diamino-1-methylpyrimidine-2,4-dione Chemical compound CN1C(N)=C(N)C(=O)NC1=O PSIJQVXIJHUQPJ-UHFFFAOYSA-N 0.000 description 2
- OJDXACZTKUCFIP-UHFFFAOYSA-N 5,6-diamino-3-(cyclopropylmethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N)=C(N)NC(=O)N1CC1CC1 OJDXACZTKUCFIP-UHFFFAOYSA-N 0.000 description 2
- LGOOOJLVNCQMNA-UHFFFAOYSA-N 5-(chloromethyl)-3-(4-chlorophenyl)-2h-oxadiazole Chemical compound N1OC(CCl)=CN1C1=CC=C(Cl)C=C1 LGOOOJLVNCQMNA-UHFFFAOYSA-N 0.000 description 2
- RUCRYNNIDGUZSR-UHFFFAOYSA-N 6-amino-1,3-dibutylpyrimidine-2,4-dione Chemical compound CCCCN1C(N)=CC(=O)N(CCCC)C1=O RUCRYNNIDGUZSR-UHFFFAOYSA-N 0.000 description 2
- AHOWVSJPUQTRNN-UHFFFAOYSA-N 6-amino-1-methyl-5-nitrosopyrimidine-2,4-dione Chemical compound CN1C(N)=C(N=O)C(=O)NC1=O AHOWVSJPUQTRNN-UHFFFAOYSA-N 0.000 description 2
- CNGIDKXHQCZDRU-UHFFFAOYSA-N 6-amino-3-(cyclopropylmethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(N)=CC(=O)N1CC1CC1 CNGIDKXHQCZDRU-UHFFFAOYSA-N 0.000 description 2
- HEIJNQPNKGGRFM-UHFFFAOYSA-N 6-amino-3-(cyclopropylmethyl)-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N=O)=C(N)NC(=O)N1CC1CC1 HEIJNQPNKGGRFM-UHFFFAOYSA-N 0.000 description 2
- RZTPHFFZOUAIHF-UHFFFAOYSA-N 6-amino-5-nitroso-3-piperidin-4-yl-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N=O)=C(N)NC(=O)N1C1CCNCC1 RZTPHFFZOUAIHF-UHFFFAOYSA-N 0.000 description 2
- UIYPHTPVYOFUJA-UHFFFAOYSA-N 7-benzyl-8-(4-hydroxyphenyl)-1,3-dipropylpurine-2,6-dione Chemical group C=1C=CC=CC=1CN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(O)C=C1 UIYPHTPVYOFUJA-UHFFFAOYSA-N 0.000 description 2
- ZYUNDISUROJEDJ-UHFFFAOYSA-N 7-benzyl-8-(4-phenylmethoxyphenyl)-1,3-dipropylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC1=CC=CC=C1 ZYUNDISUROJEDJ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IWZAITCKZZQXCV-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 IWZAITCKZZQXCV-UHFFFAOYSA-N 0.000 description 2
- LSRMIPLCSHSLEB-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-(2-methylpropyl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(CC(C)C)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 LSRMIPLCSHSLEB-UHFFFAOYSA-N 0.000 description 2
- ZZJVLBUDTBEOFR-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-methyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 ZZJVLBUDTBEOFR-UHFFFAOYSA-N 0.000 description 2
- OQUAUWTVENEQHE-UHFFFAOYSA-N 8-(4-hydroxyphenyl)-7-(phenylmethoxymethyl)-1,3-dipropylpurine-2,6-dione Chemical compound C=1C=CC=CC=1COCN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(O)C=C1 OQUAUWTVENEQHE-UHFFFAOYSA-N 0.000 description 2
- HDWMDKHMNFXXDV-UHFFFAOYSA-N 8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-1,3-dimethyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 HDWMDKHMNFXXDV-UHFFFAOYSA-N 0.000 description 2
- XTKLYAIJKXTSJD-UHFFFAOYSA-N 8-[1-[(4-fluorophenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=C(F)C=C1 XTKLYAIJKXTSJD-UHFFFAOYSA-N 0.000 description 2
- GCCPZBZDHBOWDR-UHFFFAOYSA-N 8-[4-[(5-methyl-1,2-oxazol-3-yl)methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC=1C=C(C)ON=1 GCCPZBZDHBOWDR-UHFFFAOYSA-N 0.000 description 2
- OIOHCERAXJETSD-UHFFFAOYSA-N 8-[4-[[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(ON=1)=NC=1C1=CC=C(C)C=C1 OIOHCERAXJETSD-UHFFFAOYSA-N 0.000 description 2
- JVRUYBLEXLBLLW-UHFFFAOYSA-N 8-[4-[[5-(2,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=C(OC)C=C1OC JVRUYBLEXLBLLW-UHFFFAOYSA-N 0.000 description 2
- WNDUHFKYUTXRHK-UHFFFAOYSA-N 8-[4-[[5-(2-bromophenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC=C1Br WNDUHFKYUTXRHK-UHFFFAOYSA-N 0.000 description 2
- AHJHSANRNGKAFS-UHFFFAOYSA-N 8-[4-[[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC(OC)=C1 AHJHSANRNGKAFS-UHFFFAOYSA-N 0.000 description 2
- ACBRNVRYVJLTKA-UHFFFAOYSA-N 8-[4-[[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=C(Cl)C=C1 ACBRNVRYVJLTKA-UHFFFAOYSA-N 0.000 description 2
- LHMYROXNDKDUQN-UHFFFAOYSA-N 8-[4-[[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=C(F)C=C1 LHMYROXNDKDUQN-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 101150007969 ADORA1 gene Proteins 0.000 description 2
- 102000007470 Adenosine A2B Receptor Human genes 0.000 description 2
- 108010085273 Adenosine A2B receptor Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Chemical group 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- GLDYYZLOHBXJBU-UHFFFAOYSA-N chembl27155 Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(O)C=C1 GLDYYZLOHBXJBU-UHFFFAOYSA-N 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- LADPCMZCENPFGV-UHFFFAOYSA-N chloromethoxymethylbenzene Chemical compound ClCOCC1=CC=CC=C1 LADPCMZCENPFGV-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 150000002440 hydroxy compounds Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- VTXPENWYMBLLDG-UHFFFAOYSA-N methyl 4-[3-[[4-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)phenoxy]methyl]-1,2,4-oxadiazol-5-yl]benzoate Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=C(C(=O)OC)C=C1 VTXPENWYMBLLDG-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical class OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000005156 substituted alkylene group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- IINZIKWQHUFYDS-UHFFFAOYSA-N 1,3,7-tribenzylpurine-2,6-dione Chemical compound C1=2N=CN(CC=3C=CC=CC=3)C=2C(=O)N(CC=2C=CC=CC=2)C(=O)N1CC1=CC=CC=C1 IINZIKWQHUFYDS-UHFFFAOYSA-N 0.000 description 1
- VJEMKCGKLDFTJJ-UHFFFAOYSA-N 1,3-di(butan-2-yl)-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C(C)CC)C(=O)N(C(C)CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 VJEMKCGKLDFTJJ-UHFFFAOYSA-N 0.000 description 1
- AYCQLAPRNKHPEZ-UHFFFAOYSA-N 1,3-di(butan-2-yl)-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C(C)CC)C(=O)N(C(C)CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 AYCQLAPRNKHPEZ-UHFFFAOYSA-N 0.000 description 1
- BHLDQDYIXOSLJQ-UHFFFAOYSA-N 1,3-dibutyl-8-(1h-pyrazol-4-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(CCCC)C=2N=C1C=1C=NNC=1 BHLDQDYIXOSLJQ-UHFFFAOYSA-N 0.000 description 1
- YPEAXTQQEAQNLH-UHFFFAOYSA-N 1,3-diethyl-8-(1h-pyrazol-4-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C=1C=NNC=1 YPEAXTQQEAQNLH-UHFFFAOYSA-N 0.000 description 1
- FBGQLIIOHSZUSW-UHFFFAOYSA-N 1,3-diethyl-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 FBGQLIIOHSZUSW-UHFFFAOYSA-N 0.000 description 1
- PJJLCMDBCYNWAQ-UHFFFAOYSA-N 1,3-diethyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 PJJLCMDBCYNWAQ-UHFFFAOYSA-N 0.000 description 1
- BVUSWIYHJIKWTL-UHFFFAOYSA-N 1,3-dipropyl-8-[1-[[2-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1C(F)(F)F BVUSWIYHJIKWTL-UHFFFAOYSA-N 0.000 description 1
- HKRQXRVFKQBLQK-UHFFFAOYSA-N 1,3-dipropyl-8-[1-[[4-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=C(C(F)(F)F)C=C1 HKRQXRVFKQBLQK-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- NUZXCCGZYMDNCV-UHFFFAOYSA-N 1-(2-methoxyethyl)-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCOC)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 NUZXCCGZYMDNCV-UHFFFAOYSA-N 0.000 description 1
- RAXBBOFZURAMHN-UHFFFAOYSA-N 1-(2-methylpropyl)-8-(1h-pyrazol-4-yl)-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)NC=2N=C1C=1C=NNC=1 RAXBBOFZURAMHN-UHFFFAOYSA-N 0.000 description 1
- WALBISMSNYUHII-UHFFFAOYSA-N 1-(2-methylpropyl)-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 WALBISMSNYUHII-UHFFFAOYSA-N 0.000 description 1
- BYZUKUURYSUPAW-UHFFFAOYSA-N 1-(3-ethylhexyl)-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCC(CC)CCC)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 BYZUKUURYSUPAW-UHFFFAOYSA-N 0.000 description 1
- BQOQJVNXEQTPAP-UHFFFAOYSA-N 1-(4-fluorobutyl)-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCCCF)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 BQOQJVNXEQTPAP-UHFFFAOYSA-N 0.000 description 1
- GIKOGMKUAJVTJD-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-ethyl-8-(1h-pyrazol-4-yl)-7h-purine-2,6-dione Chemical compound O=C1N(CC)C=2N=C(C3=CNN=C3)NC=2C(=O)N1CC1CC1 GIKOGMKUAJVTJD-UHFFFAOYSA-N 0.000 description 1
- SMKYWFQALZKGPC-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-ethyl-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound O=C1N(CC)C=2N=C(C3=CN(CC=4C=C(F)C=CC=4)N=C3)NC=2C(=O)N1CC1CC1 SMKYWFQALZKGPC-UHFFFAOYSA-N 0.000 description 1
- UVHMEKJMMZTAPE-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-ethyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound O=C1N(CC)C=2N=C(C3=CN(CC=4C=C(C=CC=4)C(F)(F)F)N=C3)NC=2C(=O)N1CC1CC1 UVHMEKJMMZTAPE-UHFFFAOYSA-N 0.000 description 1
- DOTYCWXTUKFRHZ-UHFFFAOYSA-N 1-(cyclopropylmethyl)-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-3-methyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C=2N=C(C3=CN(CC=4C=C(F)C=CC=4)N=C3)NC=2C(=O)N1CC1CC1 DOTYCWXTUKFRHZ-UHFFFAOYSA-N 0.000 description 1
- ZKZNUHAKIGYLOF-UHFFFAOYSA-N 1-butan-2-yl-3-methyl-8-(1h-pyrazol-4-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C(C)CC)C(=O)N(C)C=2N=C1C=1C=NNC=1 ZKZNUHAKIGYLOF-UHFFFAOYSA-N 0.000 description 1
- QXOSROYQYAUUHO-UHFFFAOYSA-N 1-butan-2-yl-3-methyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C(C)CC)C(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 QXOSROYQYAUUHO-UHFFFAOYSA-N 0.000 description 1
- UNBVMUDPNOYZJZ-UHFFFAOYSA-N 1-butan-2-yl-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-3-methyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C(C)CC)C(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 UNBVMUDPNOYZJZ-UHFFFAOYSA-N 0.000 description 1
- BVZHNRXZWXPJEX-UHFFFAOYSA-N 1-butyl-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-3-methyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 BVZHNRXZWXPJEX-UHFFFAOYSA-N 0.000 description 1
- NHFVPOFRVAXYBX-UHFFFAOYSA-N 1-ethyl-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-3-methyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 NHFVPOFRVAXYBX-UHFFFAOYSA-N 0.000 description 1
- OPWAJYNNRKCYJJ-UHFFFAOYSA-N 1-ethynyl-8-(1h-pyrazol-4-yl)-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(C#C)C(=O)NC=2N=C1C=1C=NNC=1 OPWAJYNNRKCYJJ-UHFFFAOYSA-N 0.000 description 1
- PNUAFKCXEWKDGX-UHFFFAOYSA-N 1-methyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(C)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 PNUAFKCXEWKDGX-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- DEZDSFQEEQNLBE-UHFFFAOYSA-N 2-[(5,6-diamino-2,4-dioxo-1h-pyrimidin-3-yl)methyl]butanoic acid Chemical compound CCC(C(O)=O)CN1C(=O)NC(N)=C(N)C1=O DEZDSFQEEQNLBE-UHFFFAOYSA-N 0.000 description 1
- SACXTTNOVCDKDE-UHFFFAOYSA-N 2-[(5,6-diamino-2,4-dioxopyrimidin-1-yl)methyl]butanoic acid Chemical compound CCC(C(O)=O)CN1C(N)=C(N)C(=O)NC1=O SACXTTNOVCDKDE-UHFFFAOYSA-N 0.000 description 1
- OKNWFXBHKXSAGX-UHFFFAOYSA-N 2-[(6-amino-2,4-dioxo-1h-pyrimidin-3-yl)methyl]butanoic acid Chemical compound CCC(C(O)=O)CN1C(=O)C=C(N)NC1=O OKNWFXBHKXSAGX-UHFFFAOYSA-N 0.000 description 1
- XDQMHPMJXGSUET-UHFFFAOYSA-N 2-[(6-amino-2,4-dioxopyrimidin-1-yl)methyl]butanoic acid Chemical compound CCC(C(O)=O)CN1C(N)=CC(=O)NC1=O XDQMHPMJXGSUET-UHFFFAOYSA-N 0.000 description 1
- VOBJZRMXVGCLNR-UHFFFAOYSA-N 2-[(6-amino-5-nitroso-2,4-dioxo-1h-pyrimidin-3-yl)methyl]butanoic acid Chemical compound CCC(C(O)=O)CN1C(=O)NC(N)=C(N=O)C1=O VOBJZRMXVGCLNR-UHFFFAOYSA-N 0.000 description 1
- OBGULBOMKXHVEL-UHFFFAOYSA-N 2-[(6-amino-5-nitroso-2,4-dioxopyrimidin-1-yl)methyl]butanoic acid Chemical compound CCC(C(O)=O)CN1C(N)=C(N=O)C(=O)NC1=O OBGULBOMKXHVEL-UHFFFAOYSA-N 0.000 description 1
- BSTCLDSLWFDQKY-UHFFFAOYSA-N 2-[4-[2,6-dioxo-7-(phenylmethoxymethyl)-1,3-dipropylpurin-8-yl]phenoxy]-n'-hydroxyethanimidamide Chemical compound C=1C=CC=CC=1COCN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(OCC(N)=NO)C=C1 BSTCLDSLWFDQKY-UHFFFAOYSA-N 0.000 description 1
- IXXVDFHXWWIYIR-UHFFFAOYSA-N 2-[4-[6-oxo-1-(2-oxopropyl)-3-propyl-2,7-dihydropurin-8-yl]-1H-pyrazol-5-yl]-N-phenylacetamide Chemical compound O=C(CN1CN(C=2N=C(NC=2C1=O)C=1C(=NNC=1)CC(=O)NC1=CC=CC=C1)CCC)C IXXVDFHXWWIYIR-UHFFFAOYSA-N 0.000 description 1
- TZSPOMJIFCBQKB-UHFFFAOYSA-N 2-[[8-(1-benzylpyrazol-4-yl)-2,6-dioxo-7H-purin-3-yl]methyl]butanoic acid Chemical compound C(C)C(CN1C(NC(C=2NC(=NC1=2)C=1C=NN(C=1)CC1=CC=CC=C1)=O)=O)C(=O)O TZSPOMJIFCBQKB-UHFFFAOYSA-N 0.000 description 1
- IHZFMWAJHPOENR-UHFFFAOYSA-N 2-[[8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-2,6-dioxo-3,7-dihydropurin-1-yl]methyl]butanoic acid Chemical compound C(C)C(CN1C(NC=2N=C(NC=2C1=O)C=1C=NN(C=1)CC1=CC(=CC=C1)F)=O)C(=O)O IHZFMWAJHPOENR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- MVDURWNMLXKWGS-UHFFFAOYSA-N 3-ethyl-1-propyl-8-(1h-pyrazol-4-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC)C=2N=C1C=1C=NNC=1 MVDURWNMLXKWGS-UHFFFAOYSA-N 0.000 description 1
- JPKUUKXDNMLFAX-UHFFFAOYSA-N 4-(1,3-dipropyl-7,8-dihydro-2H-purin-8-yl)phenol Chemical compound OC1=CC=C(C=C1)C1N=C2N(CN(C=C2N1)CCC)CCC JPKUUKXDNMLFAX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- AKJYGXFLPNNPAZ-UHFFFAOYSA-N 5,6-diamino-1-(2-methoxyethyl)pyrimidine-2,4-dione Chemical compound COCCN1C(N)=C(N)C(=O)NC1=O AKJYGXFLPNNPAZ-UHFFFAOYSA-N 0.000 description 1
- CGFXGMANBNXKER-UHFFFAOYSA-N 5,6-diamino-1-(2-methylpropyl)pyrimidine-2,4-dione Chemical compound CC(C)CN1C(N)=C(N)C(=O)NC1=O CGFXGMANBNXKER-UHFFFAOYSA-N 0.000 description 1
- KGFDDWNHGPNKBY-UHFFFAOYSA-N 5,6-diamino-1-(2-phenylethyl)pyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1CCC1=CC=CC=C1 KGFDDWNHGPNKBY-UHFFFAOYSA-N 0.000 description 1
- OUQOBBPXQZMVFN-UHFFFAOYSA-N 5,6-diamino-1-(3-hydroxycyclopentyl)pyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1C1CC(O)CC1 OUQOBBPXQZMVFN-UHFFFAOYSA-N 0.000 description 1
- OIRZCMGUQPXVMW-UHFFFAOYSA-N 5,6-diamino-1-(3-hydroxypropyl)pyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1CCCO OIRZCMGUQPXVMW-UHFFFAOYSA-N 0.000 description 1
- YUBRKKAZNFWPPL-UHFFFAOYSA-N 5,6-diamino-1-(4-fluorobutyl)pyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1CCCCF YUBRKKAZNFWPPL-UHFFFAOYSA-N 0.000 description 1
- GSMYCPCNIDAILQ-UHFFFAOYSA-N 5,6-diamino-1-(cyclopropylmethyl)pyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1CC1CC1 GSMYCPCNIDAILQ-UHFFFAOYSA-N 0.000 description 1
- UXLKHDZVXIDAOF-UHFFFAOYSA-N 5,6-diamino-1-(oxolan-3-yl)pyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1C1COCC1 UXLKHDZVXIDAOF-UHFFFAOYSA-N 0.000 description 1
- NUWNFQRTKKRZQE-UHFFFAOYSA-N 5,6-diamino-1-(pyridin-3-ylmethyl)pyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1CC1=CC=CN=C1 NUWNFQRTKKRZQE-UHFFFAOYSA-N 0.000 description 1
- OBWROQGNIMBKKV-UHFFFAOYSA-N 5,6-diamino-1-butylpyrimidine-2,4-dione Chemical compound CCCCN1C(N)=C(N)C(=O)NC1=O OBWROQGNIMBKKV-UHFFFAOYSA-N 0.000 description 1
- CWMNHEKWPIZIKN-UHFFFAOYSA-N 5,6-diamino-1-cyclohexylpyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1C1CCCCC1 CWMNHEKWPIZIKN-UHFFFAOYSA-N 0.000 description 1
- LULQKPJRMIFLSW-UHFFFAOYSA-N 5,6-diamino-1-cyclopentylpyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1C1CCCC1 LULQKPJRMIFLSW-UHFFFAOYSA-N 0.000 description 1
- MGZPHJXDWHXAFG-UHFFFAOYSA-N 5,6-diamino-1-ethenylpyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1C=C MGZPHJXDWHXAFG-UHFFFAOYSA-N 0.000 description 1
- OVVBFVIULMDOEE-UHFFFAOYSA-N 5,6-diamino-1-pentylpyrimidine-2,4-dione Chemical compound CCCCCN1C(N)=C(N)C(=O)NC1=O OVVBFVIULMDOEE-UHFFFAOYSA-N 0.000 description 1
- QJZONLGVDUWPED-UHFFFAOYSA-N 5,6-diamino-1-phenylpyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1C1=CC=CC=C1 QJZONLGVDUWPED-UHFFFAOYSA-N 0.000 description 1
- OODZLDDWOLCKKV-UHFFFAOYSA-N 5,6-diamino-1-piperidin-4-ylpyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1C1CCNCC1 OODZLDDWOLCKKV-UHFFFAOYSA-N 0.000 description 1
- XALGUGKCEXELMC-UHFFFAOYSA-N 5,6-diamino-1-propan-2-ylpyrimidine-2,4-dione Chemical compound CC(C)N1C(N)=C(N)C(=O)NC1=O XALGUGKCEXELMC-UHFFFAOYSA-N 0.000 description 1
- YOMSKQSCRYRZDC-UHFFFAOYSA-N 5,6-diamino-1-propylpyrimidine-2,4-dione Chemical compound CCCN1C(N)=C(N)C(=O)NC1=O YOMSKQSCRYRZDC-UHFFFAOYSA-N 0.000 description 1
- PJLYZLWECZVHEL-UHFFFAOYSA-N 5,6-diamino-1-pyridin-3-ylpyrimidine-2,4-dione Chemical compound NC1=C(N)C(=O)NC(=O)N1C1=CC=CN=C1 PJLYZLWECZVHEL-UHFFFAOYSA-N 0.000 description 1
- CUYFHEAAMHYFQW-UHFFFAOYSA-N 5,6-diamino-3-(2-methoxyethyl)-1h-pyrimidine-2,4-dione Chemical compound COCCN1C(=O)NC(N)=C(N)C1=O CUYFHEAAMHYFQW-UHFFFAOYSA-N 0.000 description 1
- RJJKHZZQSNCHQV-UHFFFAOYSA-N 5,6-diamino-3-(2-methylpropyl)-1h-pyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)NC(N)=C(N)C1=O RJJKHZZQSNCHQV-UHFFFAOYSA-N 0.000 description 1
- SOKMLEBSAPURCI-UHFFFAOYSA-N 5,6-diamino-3-(2-phenylethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N)=C(N)NC(=O)N1CCC1=CC=CC=C1 SOKMLEBSAPURCI-UHFFFAOYSA-N 0.000 description 1
- APNLLPWRUNZFJX-UHFFFAOYSA-N 5,6-diamino-3-(3-hydroxycyclopentyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N)=C(N)NC(=O)N1C1CC(O)CC1 APNLLPWRUNZFJX-UHFFFAOYSA-N 0.000 description 1
- UVUMLLAZTXXXFO-UHFFFAOYSA-N 5,6-diamino-3-(3-hydroxypropyl)-1h-pyrimidine-2,4-dione Chemical compound NC=1NC(=O)N(CCCO)C(=O)C=1N UVUMLLAZTXXXFO-UHFFFAOYSA-N 0.000 description 1
- XPUZQBSXVRBQTR-UHFFFAOYSA-N 5,6-diamino-3-(4-fluorobutyl)-1h-pyrimidine-2,4-dione Chemical compound NC=1NC(=O)N(CCCCF)C(=O)C=1N XPUZQBSXVRBQTR-UHFFFAOYSA-N 0.000 description 1
- SRMUHXXHJGSSKL-UHFFFAOYSA-N 5,6-diamino-3-(oxolan-3-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N)=C(N)NC(=O)N1C1COCC1 SRMUHXXHJGSSKL-UHFFFAOYSA-N 0.000 description 1
- NWALEXGBQPEVTD-UHFFFAOYSA-N 5,6-diamino-3-(pyridin-3-ylmethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N)=C(N)NC(=O)N1CC1=CC=CN=C1 NWALEXGBQPEVTD-UHFFFAOYSA-N 0.000 description 1
- GBMFHMBVAVUAAB-UHFFFAOYSA-N 5,6-diamino-3-benzyl-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N)=C(N)NC(=O)N1CC1=CC=CC=C1 GBMFHMBVAVUAAB-UHFFFAOYSA-N 0.000 description 1
- JCBCGVZLVYPOBV-UHFFFAOYSA-N 5,6-diamino-3-cyclohexyl-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N)=C(N)NC(=O)N1C1CCCCC1 JCBCGVZLVYPOBV-UHFFFAOYSA-N 0.000 description 1
- KOFDGZMEBAVMSB-UHFFFAOYSA-N 5,6-diamino-3-cyclopentyl-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N)=C(N)NC(=O)N1C1CCCC1 KOFDGZMEBAVMSB-UHFFFAOYSA-N 0.000 description 1
- MSMYWXWRAQPGJX-UHFFFAOYSA-N 5,6-diamino-3-ethenyl-1h-pyrimidine-2,4-dione Chemical compound NC=1NC(=O)N(C=C)C(=O)C=1N MSMYWXWRAQPGJX-UHFFFAOYSA-N 0.000 description 1
- CHEDAQQFBRYUMW-UHFFFAOYSA-N 5,6-diamino-3-ethyl-1h-pyrimidine-2,4-dione Chemical compound CCN1C(=O)NC(N)=C(N)C1=O CHEDAQQFBRYUMW-UHFFFAOYSA-N 0.000 description 1
- SMLBDIFKSNGSMR-UHFFFAOYSA-N 5,6-diamino-3-ethynyl-1h-pyrimidine-2,4-dione Chemical compound NC=1NC(=O)N(C#C)C(=O)C=1N SMLBDIFKSNGSMR-UHFFFAOYSA-N 0.000 description 1
- KNGVGMVHBVVSCF-UHFFFAOYSA-N 5,6-diamino-3-methyl-1h-pyrimidine-2,4-dione Chemical compound CN1C(=O)NC(N)=C(N)C1=O KNGVGMVHBVVSCF-UHFFFAOYSA-N 0.000 description 1
- KEEGNMSUPMTQDD-UHFFFAOYSA-N 5,6-diamino-3-phenyl-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N)=C(N)NC(=O)N1C1=CC=CC=C1 KEEGNMSUPMTQDD-UHFFFAOYSA-N 0.000 description 1
- AMGVFQCSUOQDMR-UHFFFAOYSA-N 5,6-diamino-3-propan-2-yl-1h-pyrimidine-2,4-dione Chemical compound CC(C)N1C(=O)NC(N)=C(N)C1=O AMGVFQCSUOQDMR-UHFFFAOYSA-N 0.000 description 1
- DRBZCXPJVFOQDO-UHFFFAOYSA-N 5,6-diamino-3-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCN1C(=O)NC(N)=C(N)C1=O DRBZCXPJVFOQDO-UHFFFAOYSA-N 0.000 description 1
- TUEGOQPSVVIFHD-UHFFFAOYSA-N 5,6-diamino-3-pyridin-3-yl-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N)=C(N)NC(=O)N1C1=CC=CN=C1 TUEGOQPSVVIFHD-UHFFFAOYSA-N 0.000 description 1
- WWTDBJIWQKDBSY-UHFFFAOYSA-N 5-(4-methoxyphenyl)-1,3-oxazole Chemical compound C1=CC(OC)=CC=C1C1=CN=CO1 WWTDBJIWQKDBSY-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- WPEWOBMDJKQYJK-UHFFFAOYSA-N 6-amino-1,3-diethylpyrimidine-2,4-dione Chemical compound CCN1C(N)=CC(=O)N(CC)C1=O WPEWOBMDJKQYJK-UHFFFAOYSA-N 0.000 description 1
- VFGRNTYELNYSKJ-UHFFFAOYSA-N 6-amino-1,3-dimethylpyrimidine-2,4-dione Chemical compound CN1C(N)=CC(=O)N(C)C1=O VFGRNTYELNYSKJ-UHFFFAOYSA-N 0.000 description 1
- WWYIZMBRAYKRFU-UHFFFAOYSA-N 6-amino-1,3-dipropylpyrimidine-2,4-dione Chemical compound CCCN1C(N)=CC(=O)N(CCC)C1=O WWYIZMBRAYKRFU-UHFFFAOYSA-N 0.000 description 1
- ZENYOJNRZXPEQD-UHFFFAOYSA-N 6-amino-1-(2-methoxyethyl)-5-nitrosopyrimidine-2,4-dione Chemical compound COCCN1C(N)=C(N=O)C(=O)NC1=O ZENYOJNRZXPEQD-UHFFFAOYSA-N 0.000 description 1
- YZEWEIJSLLACIN-UHFFFAOYSA-N 6-amino-1-(2-methoxyethyl)pyrimidine-2,4-dione Chemical compound COCCN1C(N)=CC(=O)NC1=O YZEWEIJSLLACIN-UHFFFAOYSA-N 0.000 description 1
- FJHKCRGGCFJZIT-UHFFFAOYSA-N 6-amino-1-(2-methylpropyl)-5-nitrosopyrimidine-2,4-dione Chemical compound CC(C)CN1C(N)=C(N=O)C(=O)NC1=O FJHKCRGGCFJZIT-UHFFFAOYSA-N 0.000 description 1
- QTAYOSNLQPIPFG-UHFFFAOYSA-N 6-amino-1-(2-methylpropyl)pyrimidine-2,4-dione Chemical compound CC(C)CN1C(N)=CC(=O)NC1=O QTAYOSNLQPIPFG-UHFFFAOYSA-N 0.000 description 1
- MYCQVAUSXCWYKG-UHFFFAOYSA-N 6-amino-1-(2-phenylethyl)pyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1CCC1=CC=CC=C1 MYCQVAUSXCWYKG-UHFFFAOYSA-N 0.000 description 1
- YGUOJYGWXYWBQE-UHFFFAOYSA-N 6-amino-1-(3-ethylhexyl)pyrimidine-2,4-dione Chemical compound CCCC(CC)CCN1C(N)=CC(=O)NC1=O YGUOJYGWXYWBQE-UHFFFAOYSA-N 0.000 description 1
- BFLMGDHMSWXONF-UHFFFAOYSA-N 6-amino-1-(3-hydroxycyclopentyl)-5-nitrosopyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1C1CC(O)CC1 BFLMGDHMSWXONF-UHFFFAOYSA-N 0.000 description 1
- IKYHRRBPIJNZFI-UHFFFAOYSA-N 6-amino-1-(3-hydroxycyclopentyl)pyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1C1CC(O)CC1 IKYHRRBPIJNZFI-UHFFFAOYSA-N 0.000 description 1
- HJDFHZIPVOZQDM-UHFFFAOYSA-N 6-amino-1-(3-hydroxypropyl)-5-nitrosopyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1CCCO HJDFHZIPVOZQDM-UHFFFAOYSA-N 0.000 description 1
- LEHHTGYPIUWCMR-UHFFFAOYSA-N 6-amino-1-(3-hydroxypropyl)pyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1CCCO LEHHTGYPIUWCMR-UHFFFAOYSA-N 0.000 description 1
- LULIGMSYWAKDED-UHFFFAOYSA-N 6-amino-1-(4-fluorobutyl)-5-nitrosopyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1CCCCF LULIGMSYWAKDED-UHFFFAOYSA-N 0.000 description 1
- RYCCSCVNLABSMS-UHFFFAOYSA-N 6-amino-1-(4-fluorobutyl)pyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1CCCCF RYCCSCVNLABSMS-UHFFFAOYSA-N 0.000 description 1
- RBTZKPJZVXWPSD-UHFFFAOYSA-N 6-amino-1-(8-aminooctan-4-yl)pyrimidine-2,4-dione Chemical compound NCCCCC(CCC)N1C(NC(C=C1N)=O)=O RBTZKPJZVXWPSD-UHFFFAOYSA-N 0.000 description 1
- FZRWTNMVIUFTPB-UHFFFAOYSA-N 6-amino-1-(8-nitrosooctan-4-yl)pyrimidine-2,4-dione Chemical compound NC1=CC(NC(N1C(CCCCN=O)CCC)=O)=O FZRWTNMVIUFTPB-UHFFFAOYSA-N 0.000 description 1
- SDWYISDPWWKTOL-UHFFFAOYSA-N 6-amino-1-(cyclopropylmethyl)-5-nitrosopyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1CC1CC1 SDWYISDPWWKTOL-UHFFFAOYSA-N 0.000 description 1
- VYJBMCHPACGHFR-UHFFFAOYSA-N 6-amino-1-(cyclopropylmethyl)pyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1CC1CC1 VYJBMCHPACGHFR-UHFFFAOYSA-N 0.000 description 1
- FHWCDIGYIODVDY-UHFFFAOYSA-N 6-amino-1-(oxolan-3-yl)pyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1C1COCC1 FHWCDIGYIODVDY-UHFFFAOYSA-N 0.000 description 1
- USGMCELSFGWLOS-UHFFFAOYSA-N 6-amino-1-(pyridin-3-ylmethyl)pyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1CC1=CC=CN=C1 USGMCELSFGWLOS-UHFFFAOYSA-N 0.000 description 1
- LTPHLWFSNYYOAG-UHFFFAOYSA-N 6-amino-1-[3-(2-aminoethyl)hexyl]pyrimidine-2,4-dione Chemical compound NCCC(CCN1C(NC(C=C1N)=O)=O)CCC LTPHLWFSNYYOAG-UHFFFAOYSA-N 0.000 description 1
- BJOKUAXJMNKHDL-UHFFFAOYSA-N 6-amino-1-[3-(2-nitrosoethyl)hexyl]pyrimidine-2,4-dione Chemical compound N(=O)CCC(CCN1C(NC(C=C1N)=O)=O)CCC BJOKUAXJMNKHDL-UHFFFAOYSA-N 0.000 description 1
- QNEUGWLDQOXAID-UHFFFAOYSA-N 6-amino-1-butyl-5-nitrosopyrimidine-2,4-dione Chemical compound CCCCN1C(N)=C(N=O)C(=O)NC1=O QNEUGWLDQOXAID-UHFFFAOYSA-N 0.000 description 1
- MKBLKULBTBPLRX-UHFFFAOYSA-N 6-amino-1-butylpyrimidine-2,4-dione Chemical compound CCCCN1C(N)=CC(=O)NC1=O MKBLKULBTBPLRX-UHFFFAOYSA-N 0.000 description 1
- WJXUHQPPUMHTFW-UHFFFAOYSA-N 6-amino-1-cyclohexyl-5-nitrosopyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1C1CCCCC1 WJXUHQPPUMHTFW-UHFFFAOYSA-N 0.000 description 1
- CLKHEAARQJQJSI-UHFFFAOYSA-N 6-amino-1-cyclohexylpyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1C1CCCCC1 CLKHEAARQJQJSI-UHFFFAOYSA-N 0.000 description 1
- QHFVYQRCYOANIO-UHFFFAOYSA-N 6-amino-1-cyclopentyl-5-nitrosopyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1C1CCCC1 QHFVYQRCYOANIO-UHFFFAOYSA-N 0.000 description 1
- QQVPYWWVYAEKFS-UHFFFAOYSA-N 6-amino-1-cyclopentylpyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1C1CCCC1 QQVPYWWVYAEKFS-UHFFFAOYSA-N 0.000 description 1
- YZFXDDUIINHYSJ-UHFFFAOYSA-N 6-amino-1-ethenyl-5-nitrosopyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1C=C YZFXDDUIINHYSJ-UHFFFAOYSA-N 0.000 description 1
- AVRKARAIJQUFFX-UHFFFAOYSA-N 6-amino-1-ethenylpyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1C=C AVRKARAIJQUFFX-UHFFFAOYSA-N 0.000 description 1
- ATYWEYAFZVJITB-UHFFFAOYSA-N 6-amino-1-ethyl-3-prop-2-ynylpyrimidine-2,4-dione Chemical compound CCN1C(N)=CC(=O)N(CC#C)C1=O ATYWEYAFZVJITB-UHFFFAOYSA-N 0.000 description 1
- YPSQTTRYMSZAGR-UHFFFAOYSA-N 6-amino-1-ethyl-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C=C(N)N(CC)C1=O YPSQTTRYMSZAGR-UHFFFAOYSA-N 0.000 description 1
- OIHHBESCFLISMR-UHFFFAOYSA-N 6-amino-1-methyl-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C=C(N)N(C)C1=O OIHHBESCFLISMR-UHFFFAOYSA-N 0.000 description 1
- VYHMTOAEYGDTLB-UHFFFAOYSA-N 6-amino-1-octan-4-ylpyrimidine-2,4-dione Chemical compound CCCCC(CCC)N1C(N)=CC(=O)NC1=O VYHMTOAEYGDTLB-UHFFFAOYSA-N 0.000 description 1
- GUSWOJVCMCNDBN-UHFFFAOYSA-N 6-amino-1-pentylpyrimidine-2,4-dione Chemical compound CCCCCN1C(N)=CC(=O)NC1=O GUSWOJVCMCNDBN-UHFFFAOYSA-N 0.000 description 1
- OSEUDSKXNZLSRV-UHFFFAOYSA-N 6-amino-1-phenylpyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1C1=CC=CC=C1 OSEUDSKXNZLSRV-UHFFFAOYSA-N 0.000 description 1
- ONBFTLQQXSJTSS-UHFFFAOYSA-N 6-amino-1-piperidin-4-ylpyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1C1CCNCC1 ONBFTLQQXSJTSS-UHFFFAOYSA-N 0.000 description 1
- FQKNOPHMINZLMQ-UHFFFAOYSA-N 6-amino-1-propan-2-ylpyrimidine-2,4-dione Chemical compound CC(C)N1C(N)=CC(=O)NC1=O FQKNOPHMINZLMQ-UHFFFAOYSA-N 0.000 description 1
- KTWOUYVBZDZRNV-UHFFFAOYSA-N 6-amino-1-propylpyrimidine-2,4-dione Chemical compound CCCN1C(N)=CC(=O)NC1=O KTWOUYVBZDZRNV-UHFFFAOYSA-N 0.000 description 1
- QGVPMTNVUJMIAX-UHFFFAOYSA-N 6-amino-1-pyridin-3-ylpyrimidine-2,4-dione Chemical compound NC1=CC(=O)NC(=O)N1C1=CC=CN=C1 QGVPMTNVUJMIAX-UHFFFAOYSA-N 0.000 description 1
- TVTIXLDDVNLXSG-UHFFFAOYSA-N 6-amino-3-(2-methoxyethyl)-1h-pyrimidine-2,4-dione Chemical compound COCCN1C(=O)C=C(N)NC1=O TVTIXLDDVNLXSG-UHFFFAOYSA-N 0.000 description 1
- GEPHTUUKPAOWEU-UHFFFAOYSA-N 6-amino-3-(2-methoxyethyl)-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound COCCN1C(=O)NC(N)=C(N=O)C1=O GEPHTUUKPAOWEU-UHFFFAOYSA-N 0.000 description 1
- HULCQAAULJKYCZ-UHFFFAOYSA-N 6-amino-3-(2-methylpropyl)-1h-pyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)C=C(N)NC1=O HULCQAAULJKYCZ-UHFFFAOYSA-N 0.000 description 1
- DJHPWVGREQYVFM-UHFFFAOYSA-N 6-amino-3-(2-methylpropyl)-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)NC(N)=C(N=O)C1=O DJHPWVGREQYVFM-UHFFFAOYSA-N 0.000 description 1
- LLCKFDMPWSYECT-UHFFFAOYSA-N 6-amino-3-(2-phenylethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(N)=CC(=O)N1CCC1=CC=CC=C1 LLCKFDMPWSYECT-UHFFFAOYSA-N 0.000 description 1
- JFVSVHLPQCPTHO-UHFFFAOYSA-N 6-amino-3-(3-hydroxycyclopentyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(N)=CC(=O)N1C1CC(O)CC1 JFVSVHLPQCPTHO-UHFFFAOYSA-N 0.000 description 1
- LGQDWXPPAYMNLC-UHFFFAOYSA-N 6-amino-3-(3-hydroxycyclopentyl)-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N=O)=C(N)NC(=O)N1C1CC(O)CC1 LGQDWXPPAYMNLC-UHFFFAOYSA-N 0.000 description 1
- MZLHGKBQNMVNTK-UHFFFAOYSA-N 6-amino-3-(3-hydroxypropyl)-1h-pyrimidine-2,4-dione Chemical compound NC1=CC(=O)N(CCCO)C(=O)N1 MZLHGKBQNMVNTK-UHFFFAOYSA-N 0.000 description 1
- JLHODNFIVNFHSX-UHFFFAOYSA-N 6-amino-3-(3-hydroxypropyl)-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound NC=1NC(=O)N(CCCO)C(=O)C=1N=O JLHODNFIVNFHSX-UHFFFAOYSA-N 0.000 description 1
- FCWDNCYKQZRTBF-UHFFFAOYSA-N 6-amino-3-(4-fluorobutyl)-1h-pyrimidine-2,4-dione Chemical compound NC1=CC(=O)N(CCCCF)C(=O)N1 FCWDNCYKQZRTBF-UHFFFAOYSA-N 0.000 description 1
- LXAMAKXAAYJWKL-UHFFFAOYSA-N 6-amino-3-(4-fluorobutyl)-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound NC=1NC(=O)N(CCCCF)C(=O)C=1N=O LXAMAKXAAYJWKL-UHFFFAOYSA-N 0.000 description 1
- RORUTZURFNBVKX-UHFFFAOYSA-N 6-amino-3-(cyclopropylmethyl)-1-ethylpyrimidine-2,4-dione Chemical compound O=C1N(CC)C(N)=CC(=O)N1CC1CC1 RORUTZURFNBVKX-UHFFFAOYSA-N 0.000 description 1
- PYHNOZBKSUHFCO-UHFFFAOYSA-N 6-amino-3-(cyclopropylmethyl)-1-methylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(N)=CC(=O)N1CC1CC1 PYHNOZBKSUHFCO-UHFFFAOYSA-N 0.000 description 1
- BJANMJLDVHJKNB-UHFFFAOYSA-N 6-amino-3-(oxolan-3-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(N)=CC(=O)N1C1COCC1 BJANMJLDVHJKNB-UHFFFAOYSA-N 0.000 description 1
- UVTOHIWWBCDHCZ-UHFFFAOYSA-N 6-amino-3-(pyridin-3-ylmethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(N)=CC(=O)N1CC1=CC=CN=C1 UVTOHIWWBCDHCZ-UHFFFAOYSA-N 0.000 description 1
- JCGJSBVUVFPNHB-UHFFFAOYSA-N 6-amino-3-benzyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(N)=CC(=O)N1CC1=CC=CC=C1 JCGJSBVUVFPNHB-UHFFFAOYSA-N 0.000 description 1
- KIGTUIJWPWWRSK-UHFFFAOYSA-N 6-amino-3-benzyl-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N=O)=C(N)NC(=O)N1CC1=CC=CC=C1 KIGTUIJWPWWRSK-UHFFFAOYSA-N 0.000 description 1
- MXIPTEGIZXADQW-UHFFFAOYSA-N 6-amino-3-butan-2-yl-1-ethylpyrimidine-2,4-dione Chemical compound CCC(C)N1C(=O)C=C(N)N(CC)C1=O MXIPTEGIZXADQW-UHFFFAOYSA-N 0.000 description 1
- OOTUTTQKWOADIZ-UHFFFAOYSA-N 6-amino-3-butan-2-yl-1-methylpyrimidine-2,4-dione Chemical compound CCC(C)N1C(=O)C=C(N)N(C)C1=O OOTUTTQKWOADIZ-UHFFFAOYSA-N 0.000 description 1
- AVIXCRCAXIJJFY-UHFFFAOYSA-N 6-amino-3-butyl-1-methylpyrimidine-2,4-dione Chemical compound CCCCN1C(=O)C=C(N)N(C)C1=O AVIXCRCAXIJJFY-UHFFFAOYSA-N 0.000 description 1
- OXKWMRNTMJQAKU-UHFFFAOYSA-N 6-amino-3-cyclohexyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(N)=CC(=O)N1C1CCCCC1 OXKWMRNTMJQAKU-UHFFFAOYSA-N 0.000 description 1
- CISVUTXAAXTUAM-UHFFFAOYSA-N 6-amino-3-cyclohexyl-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N=O)=C(N)NC(=O)N1C1CCCCC1 CISVUTXAAXTUAM-UHFFFAOYSA-N 0.000 description 1
- KGCHLBWYMGOZFI-UHFFFAOYSA-N 6-amino-3-cyclopentyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(N)=CC(=O)N1C1CCCC1 KGCHLBWYMGOZFI-UHFFFAOYSA-N 0.000 description 1
- DJAIRYRMTNYYSG-UHFFFAOYSA-N 6-amino-3-cyclopentyl-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N=O)=C(N)NC(=O)N1C1CCCC1 DJAIRYRMTNYYSG-UHFFFAOYSA-N 0.000 description 1
- NUGUIWDMBDLSQJ-UHFFFAOYSA-N 6-amino-3-ethenyl-1h-pyrimidine-2,4-dione Chemical compound NC1=CC(=O)N(C=C)C(=O)N1 NUGUIWDMBDLSQJ-UHFFFAOYSA-N 0.000 description 1
- AYOPFPHQOGXESI-UHFFFAOYSA-N 6-amino-3-ethenyl-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound NC=1NC(=O)N(C=C)C(=O)C=1N=O AYOPFPHQOGXESI-UHFFFAOYSA-N 0.000 description 1
- ZXGAVIXWLAXEGE-UHFFFAOYSA-N 6-amino-3-ethyl-1-methylpyrimidine-2,4-dione Chemical compound CCN1C(=O)C=C(N)N(C)C1=O ZXGAVIXWLAXEGE-UHFFFAOYSA-N 0.000 description 1
- XCDKMLYGJSCXIB-UHFFFAOYSA-N 6-amino-3-ethyl-1h-pyrimidine-2,4-dione Chemical compound CCN1C(=O)C=C(N)NC1=O XCDKMLYGJSCXIB-UHFFFAOYSA-N 0.000 description 1
- VKGFAIHXGKIWLT-UHFFFAOYSA-N 6-amino-3-ethyl-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound CCN1C(=O)NC(N)=C(N=O)C1=O VKGFAIHXGKIWLT-UHFFFAOYSA-N 0.000 description 1
- DREXTGZQYLMPOT-UHFFFAOYSA-N 6-amino-3-ethynyl-1h-pyrimidine-2,4-dione Chemical compound NC1=CC(=O)N(C#C)C(=O)N1 DREXTGZQYLMPOT-UHFFFAOYSA-N 0.000 description 1
- YETVCFOWEVIJGK-UHFFFAOYSA-N 6-amino-3-ethynyl-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound NC=1NC(=O)N(C#C)C(=O)C=1N=O YETVCFOWEVIJGK-UHFFFAOYSA-N 0.000 description 1
- JGAVPFNFAUWIJY-UHFFFAOYSA-N 6-amino-3-methyl-1h-pyrimidine-2,4-dione Chemical compound CN1C(=O)C=C(N)NC1=O JGAVPFNFAUWIJY-UHFFFAOYSA-N 0.000 description 1
- GUDXLMQIDACJSU-UHFFFAOYSA-N 6-amino-3-methyl-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound CN1C(=O)NC(N)=C(N=O)C1=O GUDXLMQIDACJSU-UHFFFAOYSA-N 0.000 description 1
- KADWJMOTZZAQHA-UHFFFAOYSA-N 6-amino-3-pentyl-1h-pyrimidine-2,4-dione Chemical compound CCCCCN1C(=O)C=C(N)NC1=O KADWJMOTZZAQHA-UHFFFAOYSA-N 0.000 description 1
- IRVSTVYIRDFBAG-UHFFFAOYSA-N 6-amino-3-phenyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(N)=CC(=O)N1C1=CC=CC=C1 IRVSTVYIRDFBAG-UHFFFAOYSA-N 0.000 description 1
- HTQCBWXTISNTBI-UHFFFAOYSA-N 6-amino-3-piperidin-4-yl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(N)=CC(=O)N1C1CCNCC1 HTQCBWXTISNTBI-UHFFFAOYSA-N 0.000 description 1
- OLVZIMSIXOANRW-UHFFFAOYSA-N 6-amino-3-propan-2-yl-1h-pyrimidine-2,4-dione Chemical compound CC(C)N1C(=O)C=C(N)NC1=O OLVZIMSIXOANRW-UHFFFAOYSA-N 0.000 description 1
- FPJMMVWPHPRAMW-UHFFFAOYSA-N 6-amino-3-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCN1C(=O)C=C(N)NC1=O FPJMMVWPHPRAMW-UHFFFAOYSA-N 0.000 description 1
- JWUMEYIBMPGMPA-UHFFFAOYSA-N 6-amino-3-pyridin-3-yl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(N)=CC(=O)N1C1=CC=CN=C1 JWUMEYIBMPGMPA-UHFFFAOYSA-N 0.000 description 1
- XRHKHNKSXPQOTO-UHFFFAOYSA-N 6-amino-5-nitroso-1-(2-phenylethyl)pyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1CCC1=CC=CC=C1 XRHKHNKSXPQOTO-UHFFFAOYSA-N 0.000 description 1
- LHLVXFBKIBMJID-UHFFFAOYSA-N 6-amino-5-nitroso-1-(oxolan-3-yl)pyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1C1COCC1 LHLVXFBKIBMJID-UHFFFAOYSA-N 0.000 description 1
- INVLVHDRIUPXPJ-UHFFFAOYSA-N 6-amino-5-nitroso-1-(pyridin-3-ylmethyl)pyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1CC1=CC=CN=C1 INVLVHDRIUPXPJ-UHFFFAOYSA-N 0.000 description 1
- NAJYFOLPVXVFGY-UHFFFAOYSA-N 6-amino-5-nitroso-1-pentylpyrimidine-2,4-dione Chemical compound CCCCCN1C(N)=C(N=O)C(=O)NC1=O NAJYFOLPVXVFGY-UHFFFAOYSA-N 0.000 description 1
- IBMYBOXVWGXKHZ-UHFFFAOYSA-N 6-amino-5-nitroso-1-phenylpyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1C1=CC=CC=C1 IBMYBOXVWGXKHZ-UHFFFAOYSA-N 0.000 description 1
- WKGIALILBMHYST-UHFFFAOYSA-N 6-amino-5-nitroso-1-piperidin-4-ylpyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1C1CCNCC1 WKGIALILBMHYST-UHFFFAOYSA-N 0.000 description 1
- ZTXWINIAZDSNBE-UHFFFAOYSA-N 6-amino-5-nitroso-1-propan-2-ylpyrimidine-2,4-dione Chemical compound CC(C)N1C(N)=C(N=O)C(=O)NC1=O ZTXWINIAZDSNBE-UHFFFAOYSA-N 0.000 description 1
- PJHVUYYGBOUXNX-UHFFFAOYSA-N 6-amino-5-nitroso-1-propylpyrimidine-2,4-dione Chemical compound CCCN1C(N)=C(N=O)C(=O)NC1=O PJHVUYYGBOUXNX-UHFFFAOYSA-N 0.000 description 1
- HDBBORDFDDXDRL-UHFFFAOYSA-N 6-amino-5-nitroso-1-pyridin-3-ylpyrimidine-2,4-dione Chemical compound NC1=C(N=O)C(=O)NC(=O)N1C1=CC=CN=C1 HDBBORDFDDXDRL-UHFFFAOYSA-N 0.000 description 1
- WSLAJRDFXSSOSK-UHFFFAOYSA-N 6-amino-5-nitroso-3-(2-phenylethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N=O)=C(N)NC(=O)N1CCC1=CC=CC=C1 WSLAJRDFXSSOSK-UHFFFAOYSA-N 0.000 description 1
- AOGJEKGPMZPMCF-UHFFFAOYSA-N 6-amino-5-nitroso-3-(oxolan-3-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N=O)=C(N)NC(=O)N1C1COCC1 AOGJEKGPMZPMCF-UHFFFAOYSA-N 0.000 description 1
- BUYQTUMMDSXPPR-UHFFFAOYSA-N 6-amino-5-nitroso-3-(pyridin-3-ylmethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N=O)=C(N)NC(=O)N1CC1=CC=CN=C1 BUYQTUMMDSXPPR-UHFFFAOYSA-N 0.000 description 1
- WHBYSUXASFBVKE-UHFFFAOYSA-N 6-amino-5-nitroso-3-pentyl-1h-pyrimidine-2,4-dione Chemical compound CCCCCN1C(=O)NC(N)=C(N=O)C1=O WHBYSUXASFBVKE-UHFFFAOYSA-N 0.000 description 1
- AQXGLSUXJXKOTH-UHFFFAOYSA-N 6-amino-5-nitroso-3-phenyl-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N=O)=C(N)NC(=O)N1C1=CC=CC=C1 AQXGLSUXJXKOTH-UHFFFAOYSA-N 0.000 description 1
- DNXYZZOFTCPFFI-UHFFFAOYSA-N 6-amino-5-nitroso-3-propan-2-yl-1h-pyrimidine-2,4-dione Chemical compound CC(C)N1C(=O)NC(N)=C(N=O)C1=O DNXYZZOFTCPFFI-UHFFFAOYSA-N 0.000 description 1
- MSYYROWSVFIBSJ-UHFFFAOYSA-N 6-amino-5-nitroso-3-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCN1C(=O)NC(N)=C(N=O)C1=O MSYYROWSVFIBSJ-UHFFFAOYSA-N 0.000 description 1
- MCDXBFNVQHSEMP-UHFFFAOYSA-N 6-amino-5-nitroso-3-pyridin-3-yl-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N=O)=C(N)NC(=O)N1C1=CC=CN=C1 MCDXBFNVQHSEMP-UHFFFAOYSA-N 0.000 description 1
- PUGCMFFMKHKSRK-UHFFFAOYSA-N 7-(2-methoxyethyl)-8-[4-[[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropylpurine-2,6-dione Chemical compound COCCN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC=C1OC PUGCMFFMKHKSRK-UHFFFAOYSA-N 0.000 description 1
- VPZZQWJMDWGHRG-UHFFFAOYSA-N 7-benzyl-1,3-bis(2-methylpropyl)purine-2,6-dione Chemical compound C1=2C(=O)N(CC(C)C)C(=O)N(CC(C)C)C=2N=CN1CC1=CC=CC=C1 VPZZQWJMDWGHRG-UHFFFAOYSA-N 0.000 description 1
- ZDVKDYNIGDTRGX-UHFFFAOYSA-N 7-benzyl-1,3-diethylpurine-2,6-dione Chemical compound C1=2C(=O)N(CC)C(=O)N(CC)C=2N=CN1CC1=CC=CC=C1 ZDVKDYNIGDTRGX-UHFFFAOYSA-N 0.000 description 1
- WXWQVDBZDNPNLZ-UHFFFAOYSA-N 7-benzyl-1,3-dimethylpurine-2,6-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1=CC=CC=C1 WXWQVDBZDNPNLZ-UHFFFAOYSA-N 0.000 description 1
- XDUTVTQACWYOMX-UHFFFAOYSA-N 7-benzyl-3h-purine-2,6-dione Chemical compound C1=2C(=O)NC(=O)NC=2N=CN1CC1=CC=CC=C1 XDUTVTQACWYOMX-UHFFFAOYSA-N 0.000 description 1
- KSXXBOUJUSOAIS-UHFFFAOYSA-N 7-benzyl-8-(4-hydroxyphenyl)-1,3-bis[[4-(trifluoromethyl)phenyl]methyl]purine-2,6-dione Chemical compound C1=CC(O)=CC=C1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(CC=1C=CC(=CC=1)C(F)(F)F)C(=O)N2CC1=CC=C(C(F)(F)F)C=C1 KSXXBOUJUSOAIS-UHFFFAOYSA-N 0.000 description 1
- UPAAQAIDJVLLGC-UHFFFAOYSA-N 7-benzyl-8-(4-hydroxyphenyl)-1,3-dimethylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C1=CC=C(O)C=C1 UPAAQAIDJVLLGC-UHFFFAOYSA-N 0.000 description 1
- MFFGCBDQVBOJBG-UHFFFAOYSA-N 7-benzyl-8-chloro-1,3-dimethylpurine-2,6-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=C(Cl)N1CC1=CC=CC=C1 MFFGCBDQVBOJBG-UHFFFAOYSA-N 0.000 description 1
- WSIJWSYGGJGOBF-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-1,3-di(butan-2-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C(C)CC)C(=O)N(C(C)CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 WSIJWSYGGJGOBF-UHFFFAOYSA-N 0.000 description 1
- KTFZMFONLBKWAM-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-1,3-dibutyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(CCCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 KTFZMFONLBKWAM-UHFFFAOYSA-N 0.000 description 1
- GBLDSVSFGPIOEY-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-1,3-diethyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 GBLDSVSFGPIOEY-UHFFFAOYSA-N 0.000 description 1
- MCZMFSIUZOSVRA-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-1,3-dimethyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 MCZMFSIUZOSVRA-UHFFFAOYSA-N 0.000 description 1
- IOFMLVCWZMMKRJ-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-1-(2-phenylethyl)-3,7-dihydropurine-2,6-dione Chemical compound O=C1NC=2N=C(C3=CN(CC=4C=CC=CC=4)N=C3)NC=2C(=O)N1CCC1=CC=CC=C1 IOFMLVCWZMMKRJ-UHFFFAOYSA-N 0.000 description 1
- MNSIOYQSJGYMQS-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-1-(cyclopropylmethyl)-3-methyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C=2N=C(C3=CN(CC=4C=CC=CC=4)N=C3)NC=2C(=O)N1CC1CC1 MNSIOYQSJGYMQS-UHFFFAOYSA-N 0.000 description 1
- OAORROKROOEHBB-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-1-butan-2-yl-3-ethyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C(C)CC)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 OAORROKROOEHBB-UHFFFAOYSA-N 0.000 description 1
- MYPNSGSLFUIKJV-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-1-butan-2-yl-3-methyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C(C)CC)C(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 MYPNSGSLFUIKJV-UHFFFAOYSA-N 0.000 description 1
- KWOQGNHDXLJPBS-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-1-butyl-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 KWOQGNHDXLJPBS-UHFFFAOYSA-N 0.000 description 1
- GKLKVEJQDQPJLS-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 GKLKVEJQDQPJLS-UHFFFAOYSA-N 0.000 description 1
- VBIKOSDGOHTWHU-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-(2-methoxyethyl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(CCOC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 VBIKOSDGOHTWHU-UHFFFAOYSA-N 0.000 description 1
- SBPJMPVMRWREOZ-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-(2-phenylethyl)-7H-purine-2,6-dione Chemical compound C1(=CC=CC=C1)CCN1C(NC(C=2NC(=NC1=2)C=1C=NN(C=1)CC1=CC=CC=C1)=O)=O SBPJMPVMRWREOZ-UHFFFAOYSA-N 0.000 description 1
- QGCYJIPBBPWPLP-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-(3-hydroxycyclopentyl)-7h-purine-2,6-dione Chemical compound C1C(O)CCC1N1C(=O)NC(=O)C2=C1N=C(C1=CN(CC=3C=CC=CC=3)N=C1)N2 QGCYJIPBBPWPLP-UHFFFAOYSA-N 0.000 description 1
- DUVFRVQHXKXQCN-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-(3-hydroxypropyl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(CCCO)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 DUVFRVQHXKXQCN-UHFFFAOYSA-N 0.000 description 1
- FBJBNVTXEOJEQY-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-(4-fluorobutyl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(CCCCF)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 FBJBNVTXEOJEQY-UHFFFAOYSA-N 0.000 description 1
- ZVTMQGFFLCRZQI-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-(cyclopropylmethyl)-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(C3=CN(CC=4C=CC=CC=4)N=C3)=NC=2N1CC1CC1 ZVTMQGFFLCRZQI-UHFFFAOYSA-N 0.000 description 1
- ZBEQXSUEAOGBJT-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-(oxolan-3-yl)-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(C3=CN(CC=4C=CC=CC=4)N=C3)=NC=2N1C1CCOC1 ZBEQXSUEAOGBJT-UHFFFAOYSA-N 0.000 description 1
- OZDSFSNADSAIEW-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-(pyridin-3-ylmethyl)-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(C3=CN(CC=4C=CC=CC=4)N=C3)=NC=2N1CC1=CC=CN=C1 OZDSFSNADSAIEW-UHFFFAOYSA-N 0.000 description 1
- QPQPJZBWDDDIBD-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-butyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(CCCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 QPQPJZBWDDDIBD-UHFFFAOYSA-N 0.000 description 1
- RPQJEHDWNFGHNZ-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-cyclohexyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(C3=CN(CC=4C=CC=CC=4)N=C3)=NC=2N1C1CCCCC1 RPQJEHDWNFGHNZ-UHFFFAOYSA-N 0.000 description 1
- OGMYRSWXIPAXOT-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-cyclopentyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(C3=CN(CC=4C=CC=CC=4)N=C3)=NC=2N1C1CCCC1 OGMYRSWXIPAXOT-UHFFFAOYSA-N 0.000 description 1
- DBHOBEZPHNPGKG-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-ethenyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(C=C)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 DBHOBEZPHNPGKG-UHFFFAOYSA-N 0.000 description 1
- RKOQNRKPAARGKL-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-ethyl-1-prop-2-ynyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC#C)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 RKOQNRKPAARGKL-UHFFFAOYSA-N 0.000 description 1
- RBSGLFFQVXTHGI-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-ethyl-1-propyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 RBSGLFFQVXTHGI-UHFFFAOYSA-N 0.000 description 1
- GMIZVHIQWGRKGU-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-methyl-1-propyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 GMIZVHIQWGRKGU-UHFFFAOYSA-N 0.000 description 1
- DKCWDBPNBOAZNZ-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-octan-4-yl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(C(CCC)CCCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 DKCWDBPNBOAZNZ-UHFFFAOYSA-N 0.000 description 1
- LKIRXCGACRAION-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-pentyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(CCCCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 LKIRXCGACRAION-UHFFFAOYSA-N 0.000 description 1
- BKNFGQSILULKLB-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-phenyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(C3=CN(CC=4C=CC=CC=4)N=C3)=NC=2N1C1=CC=CC=C1 BKNFGQSILULKLB-UHFFFAOYSA-N 0.000 description 1
- RSWGHBLLKDVSOV-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-piperidin-4-yl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(C3=CN(CC=4C=CC=CC=4)N=C3)=NC=2N1C1CCNCC1 RSWGHBLLKDVSOV-UHFFFAOYSA-N 0.000 description 1
- UJLAHGOHOBKDBH-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-propan-2-yl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(C(C)C)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 UJLAHGOHOBKDBH-UHFFFAOYSA-N 0.000 description 1
- CSFPQFUEAMSLTQ-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-propyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 CSFPQFUEAMSLTQ-UHFFFAOYSA-N 0.000 description 1
- XPQOALMYQZOGHS-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-7-(2-hydroxyethyl)-1,3-dipropylpurine-2,6-dione Chemical compound OCCN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 XPQOALMYQZOGHS-UHFFFAOYSA-N 0.000 description 1
- NFAAGWOWUIWLQT-UHFFFAOYSA-N 8-(4-phenylmethoxyphenyl)-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC1=CC=CC=C1 NFAAGWOWUIWLQT-UHFFFAOYSA-N 0.000 description 1
- INMYJCHAOZGGBA-UHFFFAOYSA-N 8-[1-(2-phenylethyl)pyrazol-4-yl]-1-propyl-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)NC=2N=C1C(=C1)C=NN1CCC1=CC=CC=C1 INMYJCHAOZGGBA-UHFFFAOYSA-N 0.000 description 1
- QWLQRDGWMLLCES-UHFFFAOYSA-N 8-[1-(3-cyclohexylpropyl)pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CCCC1CCCCC1 QWLQRDGWMLLCES-UHFFFAOYSA-N 0.000 description 1
- ZTLBDXCSPFQWAK-UHFFFAOYSA-N 8-[1-[(2,5-dichlorophenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC(Cl)=CC=C1Cl ZTLBDXCSPFQWAK-UHFFFAOYSA-N 0.000 description 1
- ARWUBYOBJLESLG-UHFFFAOYSA-N 8-[1-[(2-chlorophenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1Cl ARWUBYOBJLESLG-UHFFFAOYSA-N 0.000 description 1
- IFKRZKUTYVNSLN-UHFFFAOYSA-N 8-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1F IFKRZKUTYVNSLN-UHFFFAOYSA-N 0.000 description 1
- CURJJPJNMIVODA-UHFFFAOYSA-N 8-[1-[(2-methylphenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1C CURJJPJNMIVODA-UHFFFAOYSA-N 0.000 description 1
- QYQRPMNKMDEMTE-UHFFFAOYSA-N 8-[1-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC=1C(C)=NOC=1C QYQRPMNKMDEMTE-UHFFFAOYSA-N 0.000 description 1
- BHVNIIMPUODVIW-UHFFFAOYSA-N 8-[1-[(3-chlorophenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC(Cl)=C1 BHVNIIMPUODVIW-UHFFFAOYSA-N 0.000 description 1
- NMUVNLBTHYOWDK-UHFFFAOYSA-N 8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-1-(2-methylpropyl)-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 NMUVNLBTHYOWDK-UHFFFAOYSA-N 0.000 description 1
- CDIPWLHYDHZZTP-UHFFFAOYSA-N 8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-1-(3-hydroxycyclopentyl)-3,7-dihydropurine-2,6-dione Chemical compound C1C(O)CCC1N1C(=O)C(NC(=N2)C3=CN(CC=4C=C(F)C=CC=4)N=C3)=C2NC1=O CDIPWLHYDHZZTP-UHFFFAOYSA-N 0.000 description 1
- VHBXQNILRPDONL-UHFFFAOYSA-N 8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-1-(3-hydroxypropyl)-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCCO)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 VHBXQNILRPDONL-UHFFFAOYSA-N 0.000 description 1
- DXNYJJPKRIHLNM-UHFFFAOYSA-N 8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-1-(oxolan-3-yl)-3,7-dihydropurine-2,6-dione Chemical compound FC1=CC=CC(CN2N=CC(=C2)C=2NC=3C(=O)N(C4COCC4)C(=O)NC=3N=2)=C1 DXNYJJPKRIHLNM-UHFFFAOYSA-N 0.000 description 1
- AONGPVQCBIJRDU-UHFFFAOYSA-N 8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-1-(pyridin-3-ylmethyl)-3,7-dihydropurine-2,6-dione Chemical compound FC1=CC=CC(CN2N=CC(=C2)C=2NC=3C(=O)N(CC=4C=NC=CC=4)C(=O)NC=3N=2)=C1 AONGPVQCBIJRDU-UHFFFAOYSA-N 0.000 description 1
- DSKRFMSDEFWIAK-UHFFFAOYSA-N 8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-1-piperidin-4-yl-3,7-dihydropurine-2,6-dione Chemical compound FC1=CC=CC(CN2N=CC(=C2)C=2NC=3C(=O)N(C4CCNCC4)C(=O)NC=3N=2)=C1 DSKRFMSDEFWIAK-UHFFFAOYSA-N 0.000 description 1
- WFLIALIWFMRFMW-UHFFFAOYSA-N 8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-1-pyridin-3-yl-3,7-dihydropurine-2,6-dione Chemical compound FC1=CC=CC(CN2N=CC(=C2)C=2NC=3C(=O)N(C=4C=NC=CC=4)C(=O)NC=3N=2)=C1 WFLIALIWFMRFMW-UHFFFAOYSA-N 0.000 description 1
- XRNVNQOSVLRMLM-UHFFFAOYSA-N 8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-3-methyl-1-propyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 XRNVNQOSVLRMLM-UHFFFAOYSA-N 0.000 description 1
- RUBSVJWXHRWCSY-UHFFFAOYSA-N 8-[1-[(3-methoxyphenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC(OC)=C1 RUBSVJWXHRWCSY-UHFFFAOYSA-N 0.000 description 1
- ZGEGHWWAMJAODB-UHFFFAOYSA-N 8-[1-[(3-methylphenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC(C)=C1 ZGEGHWWAMJAODB-UHFFFAOYSA-N 0.000 description 1
- YOLKEFKOWBQNMM-UHFFFAOYSA-N 8-[1-[(4-chlorophenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=C(Cl)C=C1 YOLKEFKOWBQNMM-UHFFFAOYSA-N 0.000 description 1
- FHTHVMUNIOLZFP-UHFFFAOYSA-N 8-[1-[(4-methylphenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=C(C)C=C1 FHTHVMUNIOLZFP-UHFFFAOYSA-N 0.000 description 1
- QIEZGGKBPYNTKM-UHFFFAOYSA-N 8-[1-[2-(1,3-dioxoisoindol-2-yl)ethyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCN1N=CC(C2=NC=3N(C(N(CCC)C(=O)C=3N2)=O)CCC)=C1 QIEZGGKBPYNTKM-UHFFFAOYSA-N 0.000 description 1
- RLXWTYPPMJNURK-UHFFFAOYSA-N 8-[1-[[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC(ON=1)=NC=1C1=CC=C(C)C=C1 RLXWTYPPMJNURK-UHFFFAOYSA-N 0.000 description 1
- FHVPRDYQIAZXMF-UHFFFAOYSA-N 8-[1-[[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC(N=1)=NOC=1C1=CC=CC=C1OC FHVPRDYQIAZXMF-UHFFFAOYSA-N 0.000 description 1
- XEMRZUNDUPRHKB-UHFFFAOYSA-N 8-[4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC=1C(C)=NOC=1C XEMRZUNDUPRHKB-UHFFFAOYSA-N 0.000 description 1
- YWKTXZJPNNCGNV-UHFFFAOYSA-N 8-[4-[(3,5-dimethyl-2H-1,2,4-oxadiazol-5-yl)methoxy]phenyl]-1,3-dipropyl-7H-purine-2,6-dione Chemical compound CC=1NOC(N=1)(C)COC1=CC=C(C=C1)C1=NC=2N(C(N(C(C=2N1)=O)CCC)=O)CCC YWKTXZJPNNCGNV-UHFFFAOYSA-N 0.000 description 1
- JGLXCBULTZGYJY-UHFFFAOYSA-N 8-[4-[(5-cyclohexyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]-1,3-dipropyl-7H-purine-2,6-dione Chemical compound C1CC(CCC1)C1=NC(=NO1)COC1=CC=C(C=C1)C1=NC=2N(C(N(C(C=2N1)=O)CCC)=O)CCC JGLXCBULTZGYJY-UHFFFAOYSA-N 0.000 description 1
- QLTVKVLZAVCIRA-UHFFFAOYSA-N 8-[4-[(5-cyclopentyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]-1,3-dipropyl-7H-purine-2,6-dione Chemical compound C1CC(CC1)C1=NC(=NO1)COC1=CC=C(C=C1)C1=NC=2N(C(N(C(C=2N1)=O)CCC)=O)CCC QLTVKVLZAVCIRA-UHFFFAOYSA-N 0.000 description 1
- RORBDSUHBDZBTN-UHFFFAOYSA-N 8-[4-[2-(4-iodo-1h-pyrazol-5-yl)ethoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCCC1=NNC=C1I RORBDSUHBDZBTN-UHFFFAOYSA-N 0.000 description 1
- PCJJFOAAZNCMPN-UHFFFAOYSA-N 8-[4-[2-(4-methyl-1h-pyrazol-5-yl)ethoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCCC1=NNC=C1C PCJJFOAAZNCMPN-UHFFFAOYSA-N 0.000 description 1
- UIFULPIWDUCSCB-UHFFFAOYSA-N 8-[4-[[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(ON=1)=NC=1C1=CC=CC(Cl)=C1 UIFULPIWDUCSCB-UHFFFAOYSA-N 0.000 description 1
- XBJKJDCZGZYYHZ-UHFFFAOYSA-N 8-[4-[[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(ON=1)=NC=1C1=CC=C(Cl)C=C1 XBJKJDCZGZYYHZ-UHFFFAOYSA-N 0.000 description 1
- LQPZYQLMEADVDS-UHFFFAOYSA-N 8-[4-[[3-(4-propan-2-ylphenyl)-1,2,4-oxadiazol-5-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(ON=1)=NC=1C1=CC=C(C(C)C)C=C1 LQPZYQLMEADVDS-UHFFFAOYSA-N 0.000 description 1
- AJJCTKMXFBGKIW-UHFFFAOYSA-N 8-[4-[[5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC=C1Cl AJJCTKMXFBGKIW-UHFFFAOYSA-N 0.000 description 1
- WEHIFBIGHCEEOQ-UHFFFAOYSA-N 8-[4-[[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC=C1F WEHIFBIGHCEEOQ-UHFFFAOYSA-N 0.000 description 1
- BHFUUFSVLMISHM-UHFFFAOYSA-N 8-[4-[[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-7-methyl-1,3-dipropylpurine-2,6-dione Chemical compound CN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC=C1OC BHFUUFSVLMISHM-UHFFFAOYSA-N 0.000 description 1
- MOBBOKFXNBHKHE-UHFFFAOYSA-N 8-[4-[[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-7-prop-2-enyl-1,3-dipropylpurine-2,6-dione Chemical compound C=CCN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC=C1OC MOBBOKFXNBHKHE-UHFFFAOYSA-N 0.000 description 1
- UQDGXIIAMWUWLD-UHFFFAOYSA-N 8-[4-[[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-7-propan-2-yl-1,3-dipropylpurine-2,6-dione Chemical compound CC(C)N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC=C1OC UQDGXIIAMWUWLD-UHFFFAOYSA-N 0.000 description 1
- IYTGEKISEKLURT-UHFFFAOYSA-N 8-[4-[[5-(2-methylphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC=C1C IYTGEKISEKLURT-UHFFFAOYSA-N 0.000 description 1
- SNXVHAJTDNCSPB-UHFFFAOYSA-N 8-[4-[[5-(3-methylphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC(C)=C1 SNXVHAJTDNCSPB-UHFFFAOYSA-N 0.000 description 1
- PDRZVSZGCJACJG-UHFFFAOYSA-N 8-[4-[[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=C(OC)C=C1 PDRZVSZGCJACJG-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical group C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108091006101 Gi proteins Proteins 0.000 description 1
- 102000034354 Gi proteins Human genes 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical group CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- FFUYKQCSDLGVFB-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-[4-[6-oxo-1-(2-oxopropyl)-3-propyl-2,7-dihydropurin-8-yl]-1H-pyrazol-5-yl]acetamide Chemical compound CC1=C(C(=CC=C1)C)NC(CC1=NNC=C1C1=NC=2N(CN(C(C=2N1)=O)CC(C)=O)CCC)=O FFUYKQCSDLGVFB-UHFFFAOYSA-N 0.000 description 1
- GGRGRAKKZXKMHB-UHFFFAOYSA-N N-(2-chlorophenyl)-2-[4-[6-oxo-1-(2-oxopropyl)-3-propyl-2,7-dihydropurin-8-yl]-1H-pyrazol-5-yl]acetamide Chemical compound O=C(CN1CN(C=2N=C(NC=2C1=O)C=1C(=NNC=1)CC(=O)NC1=C(C=CC=C1)Cl)CCC)C GGRGRAKKZXKMHB-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- CJLJCUUZFJWBEL-UHFFFAOYSA-N N1=CC(=CC=C1)CCCN1C(NC=2N=C(NC=2C1=O)C=1C=NN(C=1)CC1=CC=CC=C1)=O Chemical compound N1=CC(=CC=C1)CCCN1C(NC=2N=C(NC=2C1=O)C=1C=NN(C=1)CC1=CC=CC=C1)=O CJLJCUUZFJWBEL-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- DNRFVTDTYNMTPA-UHFFFAOYSA-N [4-[2,6-dioxo-7-(phenylmethoxymethyl)-1,3-dipropylpurin-8-yl]phenyl] n'-hydroxycarbamimidate Chemical compound C=1C=CC=CC=1COCN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(OC(N)=NO)C=C1 DNRFVTDTYNMTPA-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- KACZQOKEFKFNDB-UHFFFAOYSA-N ethyl 1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1 KACZQOKEFKFNDB-UHFFFAOYSA-N 0.000 description 1
- CHBWTRJFVOMZKI-UHFFFAOYSA-N ethyl 2-[4-[6-oxo-1-(2-oxopropyl)-3-propyl-2,7-dihydropurin-8-yl]-1H-pyrazol-5-yl]-2-phenylacetate Chemical compound O=C(CN1CN(C=2N=C(NC=2C1=O)C=1C(=NNC=1)C(C(=O)OCC)C1=CC=CC=C1)CCC)C CHBWTRJFVOMZKI-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HGUZQMQXAHVIQC-UHFFFAOYSA-N n-methylethenamine Chemical group CNC=C HGUZQMQXAHVIQC-UHFFFAOYSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- 150000002832 nitroso derivatives Chemical class 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- UXHJOYULELWSOU-UHFFFAOYSA-N tert-butyl 8-(4-hydroxyphenyl)-1,3-dimethyl-2,6-dioxopurine-7-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C1=CC=C(O)C=C1 UXHJOYULELWSOU-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RKBCYCFRFCNLTO-UHFFFAOYSA-N triisopropylamine Chemical compound CC(C)N(C(C)C)C(C)C RKBCYCFRFCNLTO-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34822201P | 2001-11-09 | 2001-11-09 | |
US40140802P | 2002-08-05 | 2002-08-05 | |
PCT/US2002/035880 WO2003042214A2 (en) | 2001-11-09 | 2002-11-08 | A2b adenosine receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20042378L NO20042378L (no) | 2004-07-20 |
NO329692B1 true NO329692B1 (no) | 2010-12-06 |
Family
ID=26995608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20042378A NO329692B1 (no) | 2001-11-09 | 2004-06-08 | Forbindelser som er A2B-adenosinreseptorantagonister, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende forbindelsene og anvendelse av forbindelsene |
Country Status (20)
Country | Link |
---|---|
US (2) | US6825349B2 (es) |
EP (1) | EP1444233B1 (es) |
JP (1) | JP4350517B2 (es) |
KR (1) | KR100937620B1 (es) |
CN (1) | CN100467469C (es) |
AT (1) | ATE520694T1 (es) |
AU (1) | AU2002359365B2 (es) |
CA (1) | CA2466477C (es) |
CY (1) | CY1112459T1 (es) |
DK (1) | DK1444233T3 (es) |
HK (1) | HK1071127A1 (es) |
HU (1) | HU229504B1 (es) |
IL (2) | IL161867A0 (es) |
MX (1) | MXPA04004388A (es) |
NO (1) | NO329692B1 (es) |
NZ (1) | NZ532816A (es) |
PL (1) | PL370207A1 (es) |
PT (1) | PT1444233E (es) |
RU (1) | RU2318824C2 (es) |
WO (1) | WO2003042214A2 (es) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
AU2001238665A1 (en) * | 2000-02-23 | 2001-09-03 | Cv Therapeutics, Inc. | Method of identifying partial agonists of the a2a receptor |
HUP0301622A3 (en) * | 2000-07-04 | 2006-05-29 | Novo Nordisk As | Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them |
US20080194593A1 (en) * | 2001-11-09 | 2008-08-14 | Rao Kalla | A2b adenosine receptor antagonists |
US20080318983A1 (en) * | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US7304070B2 (en) * | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
MXPA03008967A (es) * | 2002-02-01 | 2004-02-12 | King Pharmaceuticals Res & Dev | Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b. |
DK1542997T3 (da) | 2002-07-24 | 2012-06-25 | Dermira Canada Inc | Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler |
CA2492855C (en) * | 2002-07-29 | 2012-09-18 | Cv Therapeutics, Inc. | Myocardial perfusion imaging using a2a receptor agonists |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
AU2011224104B2 (en) * | 2003-05-06 | 2012-06-28 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
AU2003249604B2 (en) * | 2003-05-06 | 2011-06-30 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
KR101222364B1 (ko) * | 2003-08-25 | 2013-01-15 | 트로비스 파마슈티칼스 엘엘씨 | 치환된 8-헤테로아릴 크산틴 |
EP1678181B1 (en) * | 2003-10-31 | 2008-12-31 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists |
AU2011202523B2 (en) * | 2003-11-21 | 2013-05-30 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
CA2578702A1 (en) * | 2004-09-01 | 2006-03-16 | Cv Therapeutics, Inc. | Method of wound healing using a2b adenosine receptor antagonists |
US20060159627A1 (en) * | 2004-10-15 | 2006-07-20 | Dewan Zeng | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
AU2005295437B2 (en) | 2004-10-20 | 2011-05-19 | Gilead Palo Alto, Inc. | Use of A2A adenosine receptor agonists |
WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
WO2006091936A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
WO2006091898A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
EP2301937A1 (en) * | 2005-06-16 | 2011-03-30 | Cv Therapeutics, Inc. | Prodrugs of A2b adenosine receptor antagonists |
ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
KR101494125B1 (ko) | 2006-02-03 | 2015-02-16 | 길리애드 사이언시즈, 인코포레이티드 | A2a-아데노신 수용체 효능제 및 이의 다형체의 제조 방법 |
RU2457842C2 (ru) * | 2006-03-17 | 2012-08-10 | Гайлид Пало Альто, Инк. | Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b |
US7884100B2 (en) * | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
BRPI0716174A2 (pt) * | 2006-09-01 | 2013-09-24 | Cv Therapeutics Inc | mÉtodos e composiÇÕes para aumentar a tolerabilidade de paciente durante mÉtodos de imagem do miocÁrdio. |
US7470697B2 (en) * | 2006-09-01 | 2008-12-30 | Adenosine Therapeutics, Llc | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors |
US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
WO2008042796A2 (en) * | 2006-09-29 | 2008-04-10 | Cv Therapeutics, Inc. | Methods for myocardial imaging in patients having a history of pulmonary disease |
JP2010508315A (ja) | 2006-10-30 | 2010-03-18 | ノバルティス アーゲー | 抗炎症剤としてのヘテロ環式化合物 |
CA2673653A1 (en) * | 2007-01-03 | 2008-07-17 | Cv Therapeutics, Inc. | Myocardial perfusion imaging |
WO2009076352A1 (en) * | 2007-12-11 | 2009-06-18 | Schering Corporation | Gamma secretase modulators |
WO2009088518A1 (en) * | 2008-01-11 | 2009-07-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for the treatment of cancer |
ES2442930T3 (es) | 2008-01-11 | 2014-02-14 | Novartis Ag | Pirimidinas como inhibidores de cinasas |
AU2009230679B2 (en) | 2008-03-26 | 2013-07-18 | Advinus Therapeutics Pvt. Ltd. | Heterocyclic compounds as adenosine receptor antagonist |
WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
JP2011528364A (ja) * | 2008-07-16 | 2011-11-17 | キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド | アテローム性動脈硬化症の治療 |
BRPI0918962A2 (pt) * | 2008-09-29 | 2015-12-01 | Gilead Sciences Inc | combinações de um agente de controle de taxa e um antagonista do receptor a-2-alfa para utilização em métodos tomografia computadorizada de multidetectores |
EP2405917B1 (en) | 2009-03-13 | 2014-04-23 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
WO2011005871A1 (en) | 2009-07-07 | 2011-01-13 | Pgxhealth, Llc | Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists |
EP2499142B1 (en) | 2009-11-09 | 2016-09-21 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
JP2013533882A (ja) * | 2010-06-30 | 2013-08-29 | ギリアード サイエンシーズ, インコーポレイテッド | 肺高血圧症を処置するためのa2bアデノシン受容体アンタゴニストの使用 |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
EP2616470B1 (en) * | 2010-09-13 | 2016-10-12 | Advinus Therapeutics Limited | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
EP2465859A1 (en) * | 2010-12-08 | 2012-06-20 | Life & Brain GmbH | 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists |
JP5959541B2 (ja) | 2011-02-25 | 2016-08-02 | ノバルティス アーゲー | Trk阻害剤としてのピラゾロ[1,5−a]ピリジン |
AR085942A1 (es) * | 2011-04-07 | 2013-11-06 | Gilead Sciences Inc | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio |
WO2013062762A1 (en) * | 2011-10-27 | 2013-05-02 | Proteotech Inc | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies |
CN102532137B (zh) * | 2011-12-05 | 2014-12-10 | 辽宁医学院 | 8-吡唑取代黄嘌呤类a2b腺苷受体拮抗剂及其合成方法和应用 |
JP6132853B2 (ja) * | 2011-12-27 | 2017-05-24 | アラーガン、インコーポレイテッドAllergan,Incorporated | 全身性抗炎症反応を提供する、複数のプロスタグランジン受容体で作用する化合物 |
EA028815B1 (ru) | 2013-03-15 | 2018-01-31 | Хайдра Байосайенсиз, Инк. | Замещенные ксантины и способы их применения |
WO2014153424A1 (en) * | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) |
CN104744469A (zh) * | 2014-10-31 | 2015-07-01 | 合肥平光制药有限公司 | 一种茶碱的制备方法 |
WO2017060488A1 (en) * | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
WO2017139455A1 (en) | 2016-02-10 | 2017-08-17 | Wake Forest University Health Sciences | Model system of liver fibrosis and method of making and using the same |
CN112218867B (zh) * | 2018-03-05 | 2023-11-21 | 泰昂治疗公司 | 腺苷受体拮抗剂及其用途 |
US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
KR20210061202A (ko) | 2019-11-19 | 2021-05-27 | 일동제약(주) | 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
KR20210076693A (ko) | 2019-12-16 | 2021-06-24 | 일동제약(주) | 질소를 포함하는 헤테로고리로 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
WO2024015372A1 (en) | 2022-07-14 | 2024-01-18 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4452788A (en) | 1982-04-21 | 1984-06-05 | Warner-Lambert Company | Substituted 8-phenylxanthines |
US4593095A (en) | 1983-02-18 | 1986-06-03 | The Johns Hopkins University | Xanthine derivatives |
US4558051A (en) | 1983-10-11 | 1985-12-10 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
GB8510758D0 (en) * | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
DE8817122U1 (de) | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
IT1229195B (it) | 1989-03-10 | 1991-07-25 | Poli Ind Chimica Spa | Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche. |
DE4019892A1 (de) | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
WO1995011681A1 (en) * | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
GB9415529D0 (en) * | 1994-08-01 | 1994-09-21 | Wellcome Found | Phenyl xanthine derivatives |
DE19535504A1 (de) | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
US6291501B1 (en) | 1998-02-20 | 2001-09-18 | Harbor Branch Oceanographic Institution, Inc. | Compounds and methods of use for treatment of neurogenic inflammation |
US6117878A (en) | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
DK0956855T3 (da) | 1998-04-24 | 2003-07-14 | Leuven K U Res & Dev | Immunhæmmende effekter af 8-substituerede xanthin-derivater |
DE29902571U1 (de) | 1998-05-19 | 2000-03-23 | Papst-Motoren GmbH & Co. KG, 78112 St Georgen | Elektronisch kommutierter Motor |
US6060481A (en) | 1998-05-28 | 2000-05-09 | The Penn State Research Foundation | Method for improving insulin sensitivity using an adenosine receptor antagonist |
AU754094B2 (en) * | 1998-06-01 | 2002-11-07 | Astellas Pharma Inc. | Remedies for male sterility |
GB9817623D0 (en) | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
US6437154B1 (en) | 2001-09-28 | 2002-08-20 | Council Of Scientific And Industrial Research | Process for the preparation of 10-deacetylbaccatin III |
US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
EP1636229A4 (en) * | 2003-06-06 | 2008-07-30 | Endacea Inc | ADENOSINE A1 RECEPTOR ANTAGONISTS |
-
2002
- 2002-11-08 EP EP02793897A patent/EP1444233B1/en not_active Expired - Lifetime
- 2002-11-08 WO PCT/US2002/035880 patent/WO2003042214A2/en active IP Right Grant
- 2002-11-08 AU AU2002359365A patent/AU2002359365B2/en not_active Ceased
- 2002-11-08 US US10/290,921 patent/US6825349B2/en not_active Expired - Lifetime
- 2002-11-08 MX MXPA04004388A patent/MXPA04004388A/es active IP Right Grant
- 2002-11-08 RU RU2004114210/04A patent/RU2318824C2/ru not_active IP Right Cessation
- 2002-11-08 AT AT02793897T patent/ATE520694T1/de active
- 2002-11-08 CN CNB02822258XA patent/CN100467469C/zh not_active Expired - Fee Related
- 2002-11-08 PL PL02370207A patent/PL370207A1/xx not_active Application Discontinuation
- 2002-11-08 CA CA2466477A patent/CA2466477C/en not_active Expired - Fee Related
- 2002-11-08 JP JP2003544050A patent/JP4350517B2/ja not_active Expired - Fee Related
- 2002-11-08 DK DK02793897.6T patent/DK1444233T3/da active
- 2002-11-08 KR KR1020047006955A patent/KR100937620B1/ko active IP Right Grant
- 2002-11-08 NZ NZ532816A patent/NZ532816A/en not_active IP Right Cessation
- 2002-11-08 HU HU0401925A patent/HU229504B1/hu not_active IP Right Cessation
- 2002-11-08 PT PT02793897T patent/PT1444233E/pt unknown
- 2002-11-08 IL IL16186702A patent/IL161867A0/xx unknown
-
2004
- 2004-05-06 IL IL161867A patent/IL161867A/en not_active IP Right Cessation
- 2004-06-08 NO NO20042378A patent/NO329692B1/no not_active IP Right Cessation
- 2004-09-23 US US10/947,708 patent/US7105665B2/en not_active Expired - Lifetime
-
2005
- 2005-02-12 HK HK05101136.8A patent/HK1071127A1/xx not_active IP Right Cessation
-
2011
- 2011-10-31 CY CY20111101035T patent/CY1112459T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO329692B1 (no) | Forbindelser som er A2B-adenosinreseptorantagonister, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende forbindelsene og anvendelse av forbindelsene | |
US6977300B2 (en) | A2B adenosine receptor antagonists | |
US8324224B2 (en) | A2B adenosine receptor antagonists | |
US20090137802A1 (en) | A2b adenosine receptor antagonists | |
AU2002359365A1 (en) | A2B adenosine receptor antagonists | |
US7304070B2 (en) | A2B adenosine receptor antagonists | |
EP1622908B1 (en) | Xanthine derivatives as a2b adenosine receptor antagonists | |
RU2318825C2 (ru) | Производные ксантина в качестве антагонистов a2b аденозинового рецептора | |
AU2011224104B2 (en) | A2B adenosine receptor antagonists | |
KR20060055453A (ko) | A2b 아데노신 수용체 길항제로서의 크산틴 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |